-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CvvTVYtp9eO8wj7Tc9CpuGJElleTEhgNcYhXaDzOw507rDipBjTEmhEXfiC9N54B
 IFnyoowrtpYoSIplPPb43Q==

<SEC-DOCUMENT>/in/edgar/work/20000720/0000950131-00-004417/0000950131-00-004417.txt : 20000920
<SEC-HEADER>0000950131-00-004417.hdr.sgml : 20000920
ACCESSION NUMBER:		0000950131-00-004417
CONFORMED SUBMISSION TYPE:	10-K405
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20000430
FILED AS OF DATE:		20000720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KEWAUNEE SCIENTIFIC CORP /DE/
		CENTRAL INDEX KEY:			0000055529
		STANDARD INDUSTRIAL CLASSIFICATION:	 [3821
]		IRS NUMBER:				380715562
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0430
</COMPANY-DATA>

		FILING VALUES:
			FORM TYPE:		10-K405
			SEC ACT:		
			SEC FILE NUMBER:	000-05286
			FILM NUMBER:		675873
</FILING-VALUES>

			BUSINESS ADDRESS:	
				STREET 1:		2700 W FRONT ST
				CITY:			STATESVILLE
				STATE:			NC
				ZIP:			28677
				BUSINESS PHONE:		7048737202
</BUSINESS-ADDRESS>

				MAIL ADDRESS:	
					STREET 1:		P O BOX 1842
					STREET 2:		P O BOX 1842
					CITY:			STATESVILLE
					STATE:			NC
					ZIP:			28687-1842
</MAIL-ADDRESS>

					FORMER COMPANY:	
						FORMER CONFORMED NAME:	KEWAUNEE SCIENTIFIC EQUIPMENT CORP /DE/
						DATE OF NAME CHANGE:	19861216
</FORMER-COMPANY>

						FORMER COMPANY:	
							FORMER CONFORMED NAME:	KEWAUNEE MANUFACTURING CO
							DATE OF NAME CHANGE:	19680108
</FORMER-COMPANY>
</FILER>
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K405
<SEQUENCE>1
<FILENAME>0001.txt
<DESCRIPTION>FORM 10-K405
<TEXT>

<PAGE>

               UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C.  20549

                                   FORM 10-K

[X]  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

For the fiscal year ended April 30, 2000 or
                          --------------

[_]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission file number 0-5286
                       ------

                        KEWAUNEE SCIENTIFIC CORPORATION
                        -------------------------------
            (Exact name of registrant as specified in its charter)

       Delaware                                              38-0715562
       --------                                              ----------
(State or other jurisdiction of          (IRS Employer Identification No.)
incorporation or organization)

2700 West Front Street
Statesville, North Carolina                                  28677-2927
- ---------------------------                                  ----------
(Address of principal executive offices)                     (Zip Code)

Registrant's telephone number, including area code:  (704) 873-7202
                                                     --------------
Securities registered pursuant to Section 12(b) of the Act:  None
                                                             ----
Securities registered pursuant to Section 12(g) of the Act:

                         Common Stock $2.50 par value
                         ----------------------------
                               (Title of Class)

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.  Yes   X      No _____
                                        -----

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K is not contained herein, and will not be contained, to the
best of Registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [X]

The aggregate market value of 1,799,309 shares of voting stock held by non-
affiliates of the Registrant was approximately $23,391,017 based on the last
reported sale price of the Registrant's Common Stock on July 7, 2000. (Only
shares beneficially owned by directors of the Registrant (excluding shares
subject to options) were excluded as shares held by affiliates. By including or
excluding shares owned by anyone, the Registrant does not admit for any other
purpose that any person is or is not an affiliate of the Registrant.)

As of July 7, 2000, the Registrant had outstanding 2,465,871 shares of Common
Stock.

DOCUMENTS INCORPORATED BY REFERENCE:  Those portions of Kewaunee Scientific
Corporation's annual report to stockholders for the fiscal year ended April 30,
2000, and of the proxy statement for use in connection with Kewaunee Scientific
Corporation's annual meeting of stockholders to be held on August 23, 2000,
indicated in this report are incorporated by reference into Parts I, II and III
hereof.

                                       1
<PAGE>

     Table of Contents                                         Page or Reference
     -----------------                                         -----------------

PART I

     Item 1.   Business                                               3

     Item 2.   Properties                                             5

     Item 3.   Legal Proceedings                                      5

     Item 4.   Submission of Matters to a Vote of
               Security Holders                                       5

PART II

     Item 5.   Market for Registrant' Common Equity and
               Related Stockholder Matters                            6

     Item 6.   Selected Financial Data                                6

     Item 7.   Management's Discussion and Analysis of
               Financial Condition and Results of Operations          6

     Item 7A.  Quantitative and Qualitative Disclosures About
               Market Risk                                            6

     Item 8.   Financial Statements and Supplementary Data            6

     Item 9.   Changes in and Disagreements with Accountants
               on Accounting and Financial Disclosure                 6

PART III

     Item 10.  Directors and Executive Officers of the
               Registrant                                             7

     Item 11.  Executive Compensation                                 8

     Item 12.  Security Ownership of Certain Beneficial
               Owners and Management                                  8

     Item 13.  Certain Relationships and Related Transactions         8

PART IV

     Item 14.  Exhibits, Financial Statement Schedules,
               and Reports on Form 8-K                                9

SIGNATURES                                                          S-1

                                       2
<PAGE>

                                    PART I

Item 1.   Business
- ------------------

General

          The principal business of the Registrant is the design, manufacture
and installation of scientific and technical furniture. These products are
primarily sold through purchase orders and contracts submitted by customers,
through the Registrant's dealers and commissioned agents, a national
distributor, and through competitive bids submitted by the Registrant.

          The Company's operations are classified into two business segments:
laboratory products and technical products. The laboratory products segment
principally designs, manufactures, and installs steel and wood laboratory
furniture, worksurfaces, and fume hoods. Laboratory products are sold
principally to pharmaceutical, biotechnology, industrial, chemical and
commercial research laboratories, educational institutions, health care
institutions, and governmental entities. The technical products segment
principally manufactures and sells technical furniture including network storage
systems, workstations, workbenches, computer enclosures, and related
accessories. Technical products are sold principally to manufacturing facilities
and users of computer and networking furniture.

          It is common in the laboratory furniture industry for customer orders
to require delivery at extended future dates, because the products are
frequently to be installed in buildings yet to be constructed. Changes or delays
in building construction may cause delays in delivery of the orders. Since
prices are normally quoted on a firm basis in the industry, the Registrant bears
the burden of possible increases in labor and material costs between receipt of
an order and delivery of the product.

          The need for working capital and the credit practices of the
Registrant are comparable to those of other companies selling similar products
in similar markets. Payments for the Registrant's laboratory products are
received over longer periods of time than payments for many other types of
manufactured products, thus requiring increased working capital. In addition,
payment terms associated with certain projects provide for a retention amount
until completion of the project, thus also increasing required working capital.

          The principal raw materials and products manufactured by others used
by the Registrant in its products are cold-rolled carbon and stainless steel,
hardwood lumber and plywood, paint, chemicals, resins, hardware, plumbing and
electrical fittings.  Such materials and products are purchased from multiple
suppliers and are readily available.

          The Registrant holds various patents and patent rights but does not
consider that its success or growth is dependent upon its patents or patent
rights.  The Registrant's business is not dependent upon licenses, franchises or
concessions.

          The Registrant's business is not cyclical, although sales are
sometimes lower during the Registrant's third quarter because of slower
construction activity in certain areas of the country during the winter months.
The Registrant's business is not dependent on any one or a few customers;
however, sales to VWR Scientific Products represented 11 percent, 12 percent,
and 13 percent of the Registrant's total sales in fiscal years 2000, 1999 and
1998, respectively.

          The Registrant's sales order backlog at April 30, 2000 was $31.5
million, up from $27.0 million and $24.9 million at April 30, 1999 and 1998,
respectively.  All but $1.6 million of the backlog at April 30, 2000 was
scheduled for shipment during fiscal year 2001; however, it may reasonably be
expected that delays in shipments will occur because of customer rescheduling or
delay in completion of projects which involve the installation of the
Registrant's products.  Based on past experience, the Registrant expects that
more than 90 percent of its backlog scheduled for shipment in fiscal year 2001
will be shipped during that year.

                                       3
<PAGE>

Competition

          The Registrant considers the industries in which it competes to be
highly competitive and believes that the principal competitive factors are
price, product performance, and customer service.  A significant portion of the
business of the Registrant is based upon competitive public bidding.

Research and Development

          The amount spent during the fiscal year ended April 30, 2000 on
company-sponsored research and development activities related to new products or
services or improvement of existing products or services was $783,046.  The
amounts spent for similar purposes in the fiscal years ended April 30, 1999 and
1998 were $773,816 and $822,132, respectively.

Environmental Compliance

          In the last three fiscal years, compliance with federal, state or
local provisions enacted or adopted regulating the discharge of materials into
the environment has had no material effect on the Registrant.  There is no
material capital expenditures anticipated for such purposes, and no material
effect therefrom is anticipated on the earnings or competitive position of the
Registrant.

Employees

          The number of persons employed by the Registrant at April 30, 2000 was
606.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

          Certain statements included and referenced in this report, including
the Letter to Stockholders, narrative text, captions and Management's Discussion
and Analysis of Financial Condition and Results of Operations, constitute
"forward-looking" statements within the meaning of the Private Securities
Litigation Reform Act of 1995 (the "Reform Act"). Such forward-looking
statements involve known and unknown risks, uncertainties and other factors that
could significantly impact results or achievements expressed or implied by such
forward-looking statements. These factors include, but are not limited to,
economic, competitive, governmental, and technological factors affecting the
Company's operations, markets, products, services, and prices. The cautionary
statements made pursuant to the Reform Act herein and elsewhere by the Company
should not be construed as exhaustive or as any admission regarding the adequacy
of disclosures made by the Company prior to the effective date of the Reform
Act. The Company cannot always predict what factors would cause actual results
to differ materially from those indicated by the forward-looking statements. In
addition, readers are urged to consider statements that include the terms
"believes," "belief," "expects," "plans," "objectives," "anticipates," "intends"
or the like to be uncertain and forward-looking.

Item 2.   Properties
- --------------------

          The Registrant owns and operates three plants in Statesville, North
Carolina and one in Lockhart, Texas.  The plants are involved in the production
of the Registrant's products.

          The plants in Statesville, North Carolina are located in three
separate adjacent buildings, which contain manufacturing facilities.  Sales and
marketing, administration, engineering and drafting personnel and facilities are
also located in each of the three buildings.  The Registrant's corporate offices
are located in the largest building.  The plant buildings together comprise
approximately 382,000 square feet and are located on approximately 20 acres of
land.  In addition, the Registrant leases warehouse space of 71,000 square feet
in Statesville, North Carolina.

                                       4
<PAGE>

          The plant in Lockhart, Texas is housed in a building of approximately
129,000 square feet located on approximately 30 acres.  In addition, a separate
10,000 square foot office building on this site houses certain administrative
personnel.

          All of the facilities, which the Registrant owns, are held free and
clear of any encumbrances.  The Registrant believes its facilities are suitable
for their respective uses and are adequate for its current needs.

Item 3.   Legal Proceedings
- ---------------------------

          Form time to time, the Registrant is involved in certain disputes and
litigation relating to claims arising out of its operations in the ordinary
course of business.  Further, the Registrant periodically is subject to
government audits and inspections.  The Registrant believes that any such
matters presently pending will not, individually or in the aggregate, have a
material adverse effect on the Registrant's results of operations or financial
condition.

Item 4.   Submission of Matters to a Vote of Security Holders
- -------------------------------------------------------------

          Not Applicable.

                                       5
<PAGE>

                                    PART II

Item 5.   Market for Registrant's Common Equity and Related Stockholder Matters
- -------------------------------------------------------------------------------

          Incorporated by reference from the Registrant's annual report to
stockholders for the fiscal year ended April 30, 2000, page 22, sections
entitled "Range of Market Prices" and "Quarterly Financial Data".  As of July 7,
2000, the Registrant estimates there were approximately 1,300 stockholders of
Kewaunee common shares, of which 334 were stockholders of record.

Item 6.   Selected Financial Data
- ---------------------------------

          Incorporated by reference from the Registrant's annual report to
stockholders for the fiscal year ended April 30, 2000, page 21, section entitled
"Summary of Selected Financial Data."

Item 7.   Management's Discussion and Analysis of Financial Condition and
- -------------------------------------------------------------------------
          Results of Operations
          ---------------------

          Incorporated by reference from the Registrant's annual report to
stockholders for the fiscal year ended April 30, 2000, pages 8-9, section
entitled "Management's Discussion and Analysis".

Item 7A.  Quantitative and Qualitative Disclosures About Market Risk
- --------------------------------------------------------------------

          The Registrant is exposed to market risk in the area of interest
rates. This exposure is directly related to the Registrant's credit facility,
which is priced on a floating rate basis. At April 30, 2000, advances of
$2,555,000 were outstanding under the revolving credit portion of the credit
facility. Based on this balance and the Registrant's expected use of the credit
facility, the Registrant believes that its exposure to market risk is not
material. The Registrant has not historically used interest rate swaps or other
derivative financial instruments for the purpose of hedging fluctuations in
interest rates on its floating rate debt.

Item 8.   Financial Statements and Supplementary Data
- -----------------------------------------------------

          Incorporated by reference from the Registrant's annual report to
stockholders for the fiscal year ended April 30, 2000, pages 10-20.

Item 9.   Changes in and Disagreements with Accountants on Accounting and
- -------------------------------------------------------------------------
          Financial Disclosure
          --------------------

          Not Applicable.

                                       6
<PAGE>

                                   PART III

Item 10.  Directors and Executive Officers of the Registrant
- ------------------------------------------------------------

          (a)  Incorporated by reference from the Registrant's proxy statement
for use in connection with its annual meeting of stockholders to be held on
August 23, 2000, pages 1-4, section entitled "Election of Directors".

          (b)  The names and ages of the Registrant's executive officers and
their business experience during the past five years are set forth below:

                     Executive Officers of the Registrant
                     ------------------------------------

     Name                       Age               Position
     ----                       ---               --------

Eli Manchester, Jr.             69        Chairman and Chief Executive Officer

William A. Shumaker             52        President and Chief Operating Officer

D. Michael Parker               48        Vice President-Finance,
                                          Chief Financial Officer,
                                          Treasurer and Secretary

James J. Rossi                  58        Vice President-Human Resources

Kurt P. Rindoks                 42        Vice President of Engineering and
                                          General Manager of the Resin
                                          Materials Division - Laboratory
                                          Products Group

          Eli Manchester, Jr. was elected a director of the Registrant in
November 1990.  He was elected President and Chief Executive Officer of the
Registrant on July 11, 1990.  In August 1999 he was elected Chairman, retaining
the position of Chief Executive Officer.

          William A. Shumaker was elected a director of the Registrant February
2000 and President of the Registrant in August 1999.  He has served as the Chief
Operating Officer since August 1998 when he was also elected as Executive Vice
President.  Mr. Shumaker served as Vice President and General Manager of the
Laboratory Products Group from February 1998 to August 1998.  He joined the
Registrant in December 1993 as Vice President of Sales and Marketing.

          D. Michael Parker joined the Registrant in November 1990 as Director
of Financial Reporting and Accounting and was promoted to Corporate Controller
in November 1991.  Mr. Parker has served as Vice President of Finance, Chief
Financial Officer, Treasurer and Secretary since August 1995.

          James J. Rossi joined the Registrant in March 1984 as Corporate
Director of Human Resources and has served as Vice President of Human Resources
since January 1996.

          Kurt P. Rindoks joined the Registrant in July 1985 as an engineer and
was promoted to Director of Engineering in July 1999 and to Director of Product
Development in May 1992.  He served as Vice President of Engineering and New
Product Development for the Laboratory Products Group from September 1996
through April 1998 and has served as Vice President of Engineering and General
Manager of the Resin Materials Division for the Laboratory Products Group since
May 1998.

                                       7
<PAGE>

Item 11.  Executive Compensation
- --------------------------------

          Incorporated by reference from the Registrant's proxy statement for
use in connection with its annual meeting of stockholders to be held on August
23, 2000, pages 5-7, section entitled "Executive Compensation," pages 8-9,
section entitled "Compensation Committee Report on Executive Compensation," and
page 11, section entitled "Agreements with Certain Executives."

Item 12.  Security Ownership of Certain Beneficial Owners and Management
- ------------------------------------------------------------------------

          Incorporated by reference from the Registrant's proxy statement for
use in connection with its annual meeting of stockholders to be held on August
23, 2000, pages 12-13, sections entitled "Security Ownership of Directors and
Executive Officers" and "Security Ownership of Certain Beneficial Owners."

Item 13.  Certain Relationships and Related Transactions
- --------------------------------------------------------

          Incorporated by reference from the Registrant's proxy statement for
use in connection with its annual meeting of stockholders to be held on August
23, 2000, pages 1-4, section entitled "Election of Directors" and page 11,
section entitled "Agreements with Certain Executives."

                                       8
<PAGE>

                                    PART IV

Item 14.  Exhibits, Financial Statement Schedules and Reports on Form 8-K
- -------------------------------------------------------------------------

          The following documents are filed or incorporated by reference as part
of this report:

                                                                  Page or
(a)(1)    Financial Statements                                   Reference
          --------------------                                   ---------

          Statements of Operations
           Years ended April 30, 2000, 1999 and 1998               10*

          Statements of Stockholders' Equity
           Years ended April 30, 2000, 1999 and 1998               10*

           Balance Sheets - April 30, 2000 and 1999                11*

          Statements of Cash Flows - Years ended
           April 30, 2000, 1999 and 1998                           12*

          Notes to Financial Statements                           13-19*

          Report of Independent Accountants                        20*

(a)(2)    Financial Statement Schedule
          ----------------------------

          Report of Independent Accountants on Financial
           Statement Schedules                                     10

          Schedule II - Valuation and Qualifying Accounts          11

          All other schedules for which provision is made in the applicable
          accounting regulations of the Securities and Exchange Commission are
          not required under the related instructions or are inapplicable and,
          therefore, have been omitted.

(a)(3)    Exhibits
          --------

          Exhibits required by Item 601 of Regulation S-K are listed in the
          Exhibit Index, which is attached hereto at pages S-2 through S-6 and
          which is incorporated herein by reference.

(b)       Reports on Form 8-K
          -------------------

          No reports on Form 8-K were filed during the Registrant's fiscal year
          ended April 30, 2000.

______________

*    Matters incorporated by reference to the page numbers shown in the
     Registrant's annual report to stockholders for the year ended April 30,
     2000.

                                       9
<PAGE>

       REPORT OF INDEPENDENT ACCOUNTANTS ON FINANCIAL STATEMENT SCHEDULES


To the Stockholders and Board of Directors of Kewaunee Scientific Corporation

Our audits of the financial statements referred to in our report dated May 31,
2000 appearing in the 2000 Annual Report to Shareholders of Kewaunee Scientific
Corporation (which report and financial statements are incorporated by reference
in this Annual Report on Form 10-K) also included an audit of Page 1 of the
Financial Statement Schedule listed in Item 14(a)(2) of this Form 10-K.  In our
opinion, Page 1 of this Financial Statement Schedule related to fiscal years
ended April 30, 2000, 1999 and 1998 presents fairly, in all material respects,
the information set forth therein when read in conjunction with the related
financial statements.



PRICEWATERHOUSECOOPERS LLP
Charlotte, North Carolina
May 31, 2000

                                       10
<PAGE>

                                                             Schedule II, Page 1


                        Kewaunee Scientific Corporation
                       Valuation and Qualifying Accounts
                               ($ in thousands)

<TABLE>
<CAPTION>
                                     Balance at
                                     Beginning    Bad Debt                 Balance at
          Description                of Period    Expense    Deductions*  End of Period
          -----------                ---------    -------    ----------   -------------
<S>                                  <C>          <C>        <C>          <C>
Year ended April 30, 2000
  Allowance for doubtful accounts      $387        $123        $ (20)         $490
                                       ====        ====        =====          ====
Year ended April 30, 1999
  Allowance for doubtful accounts      $656        $ 16        $(285)         $387
                                       ====        ====        =====          ====
Year ended April 30, 1998
  Allowance for doubtful accounts      $770        $301        $(415)         $656
                                       ====        ====        =====          ====
</TABLE>

*    Uncollectible accounts written off, net of recoveries.

                                       11
<PAGE>

                                   SIGNATURES

          Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.

                         KEWAUNEE SCIENTIFIC CORPORATION

                         By: /s/ Eli Manchester, Jr.
                            -------------------------
                             Eli Manchester, Jr.
                             Chairman and Chief Executive Officer

Date: July 20, 2000

          Pursuant to the requirements of the Securities Exchange Act of 1934,
the following persons on behalf of the Registrant and in the capacities and on
the dates indicated have signed this report below.

<TABLE>
<S>                                                                               <C>
(i)       Principal Executive Officer                                             )
                                                                                  )
          /s/ Eli Manchester, Jr.                                                 )
          -------------------------------------
          Eli Manchester, Jr.                                                     )
          Chairman and Chief Executive Officer                                    )
                                                                                  )
(ii)      Principal Financial and accounting Officer                              )
                                                                                  )
          /s/ D. Michael Parker                                                   )
          -------------------------------------
          D. Michael Parker                                                       )
          Vice President-Finance, Chief Financial Officer                         )
          Treasurer and Secretary                                                 )
                                                                                  )
(iii)     A majority of the Board of Directors:                                   ) July 20, 2000
                                                                                  )
                                                                                  )
 /s/ Margaret Barr Bruemmer                       /s/ Eli Manchester, Jr.         )
- -----------------------------------               --------------------------------
Margaret Barr Bruemmer                            Eli Manchester, Jr.             )
                                                                                  )
                                                                                  )
 /s/ Wiley N. Caldwell                            /s/ James T. Rhind              )
- -----------------------------------               --------------------------------
Wiley N. Caldwell                                 James T. Rhind                  )
                                                                                  )
                                                                                  )
 /s/ John C. Campbell, Jr.                        /s/ Thomas F. Pyle              )
- -----------------------------------               --------------------------------
John C. Campbell, Jr.                             Thomas F. Pyle                  )
                                                                                  )
                                                                                  )
/s/ Kingman Douglass                              /s/ William A. Shumaker         )
- -----------------------------------               --------------------------------
Kingman Douglass                                  William A. Shumaker             )
</TABLE>

                                      S-1
<PAGE>

                        KEWAUNEE SCIENTIFIC CORPORATION

                                 Exhibit Index
                                 -------------

                                                                     Page Number
                                                                  (or Reference)
                                                                  --------------

     3    Articles of incorporation and by-laws

          3.1    Restated Certificate of
                 incorporation (as amended)                             (3)

          3.2    By-Laws (as amended as of August 28, 1991)             (6)

          3.3    Amendment dated August 26, 1999 to the Bylaws of
                 Kewaunee Scientific Corporation                       (14)

     10   Material Contracts

          10.9   Kewaunee Scientific Corporation
                 Supplemental Retirement Plan                           (4)

          10.13  Kewaunee Scientific Corporation 1985
                 Re-Established Retirement Plan for
                 Salaried Employees                                     (2)

          10.13A First Amendment dated June 4, 1996 to the
                 Kewaunee Scientific Corporation 1985
                 Re-Established Retirement Plan for
                 Salaried Employees                                    (11)

          10.13B Second Amendment dated November 19, 1996 to the
                 Kewaunee Scientific Corporation 1985
                 Re-Established Retirement Plan for
                 Salaried Employees                                    (11)

          10.14  Kewaunee Scientific Corporation 1985
                 Re-Established Retirement Plan for
                 Hourly Employees                                       (2)

          10.14A First Amendment dated August 27, 1996 to the
                 Kewaunee Scientific Corporation 1985
                 Re-Established Retirement Plan for
                 Hourly Employees                                      (11)

          10.14B Second Amendment dated November 19, 1996 to the
                 Kewaunee Scientific Corporation 1985
                 Re-Established Retirement Plan for
                 Hourly Employees                                      (11)

                                      S-2
<PAGE>

                                                                     Page Number
                                                                  (or Reference)
                                                                  --------------

          10.19   Kewaunee Scientific Corporation 1991
                  Key Employee Stock Option Plan                         (5)

          10.19A  First Amendment dated August 28, 1996 to the
                  Kewaunee Scientific Corporation
                  Key Employee Stock Option Plan                        (10)

          10.19B  Second Amendment dated August 26, 1998 to the
                  Kewaunee Scientific Corporation
                  Key Employee Stock Option Plan                        (13)

          10.21   Kewaunee Scientific Corporation
                  Executive Deferred Compensation Plan                   (6)

          10.21A  Second Amendment dated June 17, 1997 to the
                  Kewaunee Scientific Corporation Executive
                  Deferred Compensation Plan                            (12)

          10.21B  Third Amendment dated June 17, 1997 to the
                  Kewaunee Scientific Corporation Executive
                  Deferred Compensation Plan                            (12)

          10.21C  Fourth Amendment dated December 1, 1998 to the
                  Kewaunee Scientific Corporation Executive
                  Deferred Compensation Plan                            (13)

          10.25   Employment Agreement dated as of December 7, 1993
                  between William A. Shumaker and the Registrant         (8)

          10.26   Kewaunee Scientific Corporation
                  Stock Option Plan for Directors                        (7)

          10.34   401(K) Incentive Savings Plan
                  for Salaried and Hourly Employees of
                  Kewaunee Scientific Corporation                        (9)

          10.34A  Amendments (2) dated June 17, 1997 to the 401(K)
                  Incentive Savings plan for Salaried and Hourly
                  Employees of Kewaunee Scientific Corporation          (12)

                                      S-3
<PAGE>

<TABLE>
<CAPTION>
                                                                          Page Number
                                                                        (or Reference)
                                                                         ------------
     <S>                                                                 <C>
          10.36  Agreement dated September 17, 1996
                 between D. Michael Parker and the Registrant                    (11)

          10.38  Change of Control agreement dated as of November 12, 1999
                 between William A. Shumaker and the Registrant.                 (15)

          10.39  Change of Control agreement dated as of November 12, 1999
                 between D. Michael Parker and the Registrant.                   (15)

          10.40  Change of Control agreement dated as of November 12, 1999
                 between James J. Rossi and the Registrant.                      (15)

          10.41  Change of Control agreement dated as of January 20, 2000
                 between Kurt P. Rindoks and the Registrant.                     (15)

          10.42  Kewaunee Scientific Corporation
                 Pension Equalization Plan                                        (1)

          10.42A First Amendment dated May 27, 1999 to the
                 Kewaunee Scientific Corporation
                 Pension Equalization Plan                                        (1)

          10.43  Fiscal Year 2001 Incentive Bonus Plan                            (1)

     13   Annual Reports to Stockholders for the fiscal year ended April 30,
          2000 (Such Report, except to the extent incorporated herein by
          reference, is being furnished for the information of the Securities
          and Exchange Commission only and is not deemed filed as a part of this
          annual report on Form 10-K)                                             (1)

     27   Financial Data Schedule                                                 (1)
</TABLE>

(All other exhibits are either inapplicable or not required.)

                                      S-4
<PAGE>

                                   Footnotes

(1)  Filed with this Form 10-K with the Securities and Exchange Commission.

(2)  Filed as an exhibit to the Kewaunee Scientific Corporation Annual Report to
     the Securities and Exchange Commission on Form 10-K (Commission File No.
     0-5286) for the fiscal year ended April 30, 1987, and incorporated herein
     by reference.

(3)  Filed as an exhibit to the Kewaunee Scientific Corporation Annual Report to
     the Securities and Exchange Commission on Form 10-K (Commission File No.
     0-5286) for the fiscal year ended April 30, 1985, and incorporated herein
     by reference.

(4)  Filed as an exhibit to the Kewaunee Scientific Corporation Annual Report to
     the Securities and Exchange Commission on Form 10-K (Commission File No.
     0-5286) for the fiscal year ended April 30, 1985, and incorporated herein
     by reference.

(5)  Filed as an exhibit to the Kewaunee Scientific Corporation Proxy Statement
     dated July 26, 1991, and incorporated herein by reference.

(6)  Filed as an exhibit to the Kewaunee Scientific Corporation Annual Report to
     the Securities and Exchange Commission on Form 10-K (Commission File No.
     0-5286) for the fiscal year ended April 30, 1992, and incorporated herein
     by reference.

(7)  Filed as an exhibit to the Kewaunee Scientific Corporation Proxy Statement
     dated July 23, 1993, and incorporated herein by reference.

(8)  Filed as an exhibit to the Kewaunee Scientific Corporation Annual Report to
     the Securities and Exchange Commission on Form 10-K (Commission File No.
     0-5286) for the fiscal year ended April 30, 1994, and incorporated herein
     by reference.

(9)  Filed as an exhibit to the Kewaunee Scientific Corporation Annual Report to
     the Securities and Exchange Commission on Form 10-K (Commission File No.
     0-5286) for the fiscal year ended April 30, 1996, and incorporated herein
     by reference.

(10) Filed as an exhibit to the Kewaunee Scientific Corporation Proxy Statement
     dated July 31, 1996, and incorporated herein by reference.

(11) Filed as an exhibit to the Kewaunee Scientific Corporation Annual Report to
     the Securities and Exchange Commission on Form 10-K (Commission File No.
     0-5286) for the fiscal year ended April 30, 1997, and incorporated herein
     by reference.

(12) Filed as an exhibit to the Kewaunee Scientific Corporation Annual Report to
     the Securities and Exchange Commission on Form 10-K (Commission File No.
     0-5286) for the fiscal year ended April 30, 1998, and incorporated herein
     by reference.

(13) Filed as an exhibit to the Kewaunee Scientific Corporation Annual Report to
     the Securities and Exchange Commission on Form 10-K (Commission File No.
     0-5286) for the fiscal year ended April 30, 1999, and incorporated herein
     by reference.

(14) Filed as an exhibit to the Kewaunee Scientific Corporation Quarterly Report
     to the Securities and Exchange Commission on Form 10-Q (Commission File No.
     0-5286) for the quarterly period ended October 31, 1999, and incorporated
     herein by reference.

(15) Filed as an exhibit to the Kewaunee Scientific Corporation Quarterly Report
     to the Securities and Exchange Commission on Form 10-Q (Commission File No.
     0-5286) for the quarterly period ended January 31, 2000, and incorporated
     herein by reference.

                                      S-5
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42
<SEQUENCE>2
<FILENAME>0002.txt
<DESCRIPTION>KWEAUNEE PENSION EQUALIZATION PLAN
<TEXT>

<PAGE>

                                                                           10.42

                        KEWAUNEE SCIENTIFIC CORPORATION
                           PENSION EQUALIZATION PLAN
                            (Effective May 1, 1999)
<PAGE>

                        KEWAUNEE SCIENTIFIC CORPORATION
                           PENSION EQUALIZATION PLAN
                            (Effective May 1, 1999)

<TABLE>
<S>                                                          <C>
Article I............................................         1
     Establishment and Purpose.......................         1
        1.1      The Plan............................         1
        1.2      Purpose.............................         1
        1.3      Plan Year...........................         1

Article II...........................................         1
     Administration and Participation................         1
        2.1      Administration......................         1
        2.2      Participation.......................         2

Article III..........................................         3
     Amount and Payment of Benefits..................         3
        3.1      Amount of Benefit...................         3
        3.2      Time and Form of Payment............         3
        3.3      Vesting.............................         4
        3.4      Death Benefits......................         4

Article IV...........................................         4
     Payment.........................................         4
        4.1      Source of Payment...................         4
        4.2      Withholding Taxes...................         4
        4.3      Disabled or Missing Participants....         5
        4.4      Claims..............................         5

Article V............................................         6
     General Provisions..............................         6
        5.1      Interests Not Transferable..........         6
        5.2      Plan Not an Employment Contract.....         7
        5.3      Effect on Other Benefit Plans.......         7
        5.4      Funding.............................         7
        5.5      Litigation..........................         8
        5.6      Cooperation.........................         8
        5.7      Severability........................         9
        5.8      Applicable Law......................         9

Article VII..........................................         9
     Amendment and Termination.......................         9

Exhibit A............................................        11
     List of Initial Participants....................        11
</TABLE>
<PAGE>

                        KEWAUNEE SCIENTIFIC CORPORATION
                           PENSION EQUALIZATION PLAN
                            (Effective May 1, 1999)

                                  Article I.
                                  ---------
                           Establishment and Purpose
                           -------------------------

     1.1  The Plan.  The KEWAUNEE SCIENTIFIC CORPORATION PENSION EQUALIZATION
          --------
PLAN (the "Plan") was established by Kewaunee Scientific Corporation (the
"Company"), effective May 1, 1999.

     1.2  Purpose.  The Plan is intended to be an unfunded "top-hat" plan
          -------
maintained for the purpose of providing a select group of management or highly
compensated employees with the full amount of retirement income that they or
their beneficiaries would be entitled to receive under the Re-Established
Retirement Plan for Salaried Employees of Kewaunee Scientific Corporation (the
"Retirement Plan") but for the limits imposed by the Internal Revenue Code on
the amount of compensation taken into account under the Retirement Plan.  The
purpose of the Plan is to advance the interests of the Company by providing such
retirement income so as to attract and retain such employees and make their
compensation competitive with other opportunities.

     1.3  Plan Year.  The Plan is maintained by the Company on the basis of a
          ---------
"Plan Year" which commences on May 1 of each calendar year and ends on April 30
of the following calendar year.

                                  Article II.
                                  ----------
                       Administration and Participation.
                       --------------------------------

     2.1  Administration.  Full power and authority to construe, interpret and
          --------------
administer the Plan shall be vested in a committee (the "Committee") composed of
the Compensation Committee of the Board of Directors of the Company.  The
Committee shall make each
<PAGE>

determination provided for under the Plan and promulgate such rules and
regulations as may be required for the implementation or management of the Plan.
The Committee may delegate all or any portion of its authority to such persons
as it may determine, and may revoke or revise any such delegation at any time.
Unless and until otherwise determined by the Committee, the authority of the
Committee to establish rules, regulations and procedures that are administrative
or ministerial in nature shall be exercised by the Company's Vice President of
Human Resources (or such other officer or employee of the Company as may occupy
a comparable position). The determinations of the Committee, or of any person to
whom the Committee's authority has been delegated, shall be final and binding on
all persons (except for the right of appeal set forth in Section 4.4).

     2.2  Participation.  Participation in the Plan shall be limited to a
          -------------
select group of management or highly compensated employees of the Company.  The
initial Participants in the Plan are listed on Exhibit A hereto.  Additional
management or highly compensated employees shall become Participants only upon
being recommended for participation by the President of the Company and approved
by the Committee.  The mere fact that any employee receives compensation in
excess of the amount that may be taken into account under the Retirement Plan
shall not in itself entitle the employee to participate in the Plan.  Nothing
contained in the Plan shall confer upon any Participant any right to be
continued in the employ of the Company or interfere in any way with the right of
the Company to terminate a Participant's employment at any time.

                                      -2-
<PAGE>

                                 Article III.
                                 -----------
                        Amount and Payment of Benefits.
                        ------------------------------

     3.1  Amount of Benefit.  The benefit payable to each Participant, or to
          -----------------
any beneficiary of a Participant, pursuant to this Plan shall be equal to the
excess, if any, of (i) the benefit that would have been payable to such
Participant or beneficiary under the Retirement Plan if the Participant's
compensation taken into account under the Retirement Plan were not limited under
Section 401(a)(17) of the Internal Revenue Code (or any successor to such
provision, as determined by the Committee), over (ii) the benefit actually paid
to such Participant or beneficiary under the Retirement Plan.  In no event shall
the sum of the benefit paid under the Retirement Plan and the benefit paid under
this Plan exceed the benefit that would have been paid under the Retirement Plan
in the absence of Section 401(a)(17) of the Code.

     3.2  Time and Form of Payment. Benefits payable under this Plan to any
          ------------------------
Participant or beneficiary shall be paid at the same time and in the same form
as the benefits paid to the Participant or beneficiary under the Retirement
Plan, taking into account any elections made by the Participant under the
Retirement Plan.  Each Participant or beneficiary shall receive at the time each
benefit payment is made pursuant to the Retirement Plan a supplemental payment
under this Plan equal to the difference, if any, described in Section 3.1.
Notwithstanding the foregoing, (i) the Committee may in its sole discretion at
any time accelerate the payment of any benefits due to any Participant or
beneficiary under this Plan, in which event the remaining amount owed to such
Participant or beneficiary shall be reduced by the actuarial equivalent of the
accelerated payment, and (ii) if the actuarial present value of the benefits due
to any Participant or beneficiary at the time benefits are due to commence does
not exceed $20,000, the amount of such present value shall be paid to such
Participant or beneficiary in a single lump sum, which

                                      -3-
<PAGE>

shall fully discharge all obligations to such Participant or beneficiary under
the Plan. For purposes of the preceding sentence, actuarial equivalent shall be
determined on the basis of the factors used for comparable computations under
the Retirement Plan.

     3.3  Vesting.  A Participant's benefits under this Plan shall be vested
          -------
to the same extent as his benefit under the Retirement Plan and shall be
forfeited only if and to the extent his Retirement Plan benefit is forfeited.

     3.4  Death Benefits.  A Participant's beneficiary under this Plan shall
          --------------
be the person entitled to receive any survivorship benefits payable with respect
to such Participant under the Retirement Plan, and such beneficiary shall be
entitled to the supplemental payments with respect to such survivorship benefits
described in Section 3.2 above.  Except for such payments, no survivorship or
other benefits shall be payable to any person by reason of the death of the
Participant.

                                  Article IV.
                                  ----------
                                   Payment.
                                   -------

     4.1  Source of Payment.  All benefits payable under this Plan shall be
          -----------------
paid either directly by the Company, or by a distribution from the Irrevocable
Grantor Trust described in Section 5.4.  The establishment and funding of the
Irrevocable Grantor Trust shall not relieve the Company of its obligations under
this Plan, but all amounts actually paid to a Participant or beneficiary from
the Irrevocable Grantor Trust shall reduce the obligation of the Company to the
extent of such payment.

     4.2  Withholding Taxes.  The Company may withhold from a Participant's
          -----------------
compensation or any payment under this Plan any taxes required to be withheld
with respect to benefits under this Plan.

                                      -4-
<PAGE>

     4.3  Disabled or Missing Participants.  If any person entitled to the
          --------------------------------
payment of benefits under the Plan is under a legal disability, or in the
Company's opinion, is incapacitated in any way so as to be unable to manage his
financial affairs, the Committee may direct the payment of such distribution to
such person's legal representative or to a relative or friend of such person for
such person's benefit.  If the Company is unable to locate any Participant or
beneficiary, and the Participant or beneficiary fails to contact the Company
after being notified of his right to receive a benefit by a letter sent to his
last address on file with the Company, then the Committee may, in its
discretion, either cause such benefit to be paid to another member of the
Participant's family or treat such benefit as forfeited.  Any payments or
forfeiture made in accordance with this Section 4.3 shall discharge fully all
obligations for such benefits under the Plan.

     4.4  Claims.  A Participant or beneficiary, or an authorized
          ------
representative acting on his behalf (hereinafter called the "claimant"), may
notify the Committee of a claim for benefits under the Plan.  Such notice may be
made in writing on a form specified by the Committee and shall set forth the
basis of such claim and shall authorize the Committee to conduct such
examinations as may be necessary to determine the validity of the claim and to
take such steps as may be necessary to facilitate the payment of any benefits to
which the claimant may be entitled under the terms of the Plan.

     Claims shall initially be processed by the person to whom the Committee's
authority over administrative matters has been delegated pursuant to Section
2.1, or such person as he may designate.  Whenever a claim for benefits by the
claimant has been denied, a written notice of denial shall be given to the
claimant, prepared in a manner calculated to be understood by him without legal
assistance and setting forth the specific reasons for the denial and explaining
the

                                      -5-
<PAGE>

procedure for an appeal and review of the decision by the Committee.  Such
notice shall be furnished not later than 90 days after the claim has been filed
(which 90 day period may be extended for up to an additional 90 days if special
circumstances require and notice of the extension is furnished to the claimant
prior to the end of the first 90 day period).

     A claimant whose claim is denied, or his authorized representative, may
request a review upon written application to the Committee within 60 days after
receiving notice of the denial.  In connection with such application, the
claimant or his authorized representative may review pertinent documents and may
submit issues and comments in writing.  If such an application is made, the
Committee shall make a full and fair review of the denial of the claim and shall
make a decision not later than its first meeting that is held at least 30 days
after receipt of the application, unless special circumstances (such as the need
to hold a hearing) require an extension of time, in which case a decision shall
be made as soon as possible but not later than the second such meeting.  If a
request for review is received at a time when the Committee does not hold
regularly scheduled meetings at least once a quarter, the decision shall be made
not later than 60 days after the request is received, which may be extended to
up to 120 days if special circumstances require.  The decision on review shall
be in writing and shall include specific reasons for the decision and specific
references to the pertinent provisions of the Plan on which the decision is
based.

                                  Article V.
                                  ---------
                              General Provisions.
                              ------------------

     5.1  Interests Not Transferable.  The interests of the Participants and
          --------------------------
their beneficiaries under the Plan are not subject to the claims of their
creditors and may not be voluntarily or involuntarily transferred, assigned,
alienated, or encumbered.  Notwithstanding the foregoing, the

                                      -6-
<PAGE>

Company may offset against any benefits payable to or on behalf of any
Participant any amount owed to it or to any of its affiliates by such
Participant, and may withhold payment of any such benefit until the amount owed
by such Participant has been determined.

     5.2  Plan Not an Employment Contract.  This Plan is not an employment
          -------------------------------
contract.  It does not give to any person the right to be continued in
employment, and all employees remain subject to change of salary, transfer,
change of job, discipline, layoff, discharge, or any other change of employment
status.

     5.3  Effect on Other Benefit Plans.  Amounts credited or paid under this
          -----------------------------
Plan, and the amount of any pay reduced pursuant to section 3.1, shall not be
considered to be compensation for the purposes of any qualified plan maintained
by the Company.  The treatment of such amounts under other employee benefit
plans shall be determined pursuant to the provisions of such plans.

     5.4  Funding.  The Company shall make payment of its contributions under
          -------
the Plan to the Company's Irrevocable Grantor Trust (which has been established
in connection with this Plan), either in cash or by the delivery to the trustee
thereunder of insurance contracts, in such amounts as the Company shall
reasonably decide are necessary to provide for all benefits payable under the
Plan.  The establishment and funding of the Irrevocable Grantor Trust shall not
relieve the Company of its obligations under this Plan, but any amount actually
paid by the Irrevocable Grantor Trust to a Participant or beneficiary shall be
credited against the amount owed by the Company to such Participant or
beneficiary under the Plan.  No employee shall have any right, title, or
interest whatever in or to any insurance contracts, investment reserves,
accounts, funds or grantor trusts that the Company may purchase, establish, or
accumulate to aid in providing the benefits under this Plan.  Neither an
employee nor a beneficiary of an employee shall acquire any

                                      -7-
<PAGE>

interest greater than that of an unsecured creditor of the Company. Any assets
of the Company or of any trust or other fund of the Company from which Plan
benefits may be paid shall remain in all respects assets of the Company until
payments of such benefits are actually made. Nothing contained in this Plan, and
no action taken pursuant to its provisions, shall create a trust or fiduciary
relationship of any kind between the Company and an employee or any other
person.

     5.5  Litigation.  In any action or proceeding regarding the Plan,
          ----------
Participants or their beneficiaries or any other persons having or claiming to
have an interest in this Plan shall not be necessary parties and shall not be
entitled to any notice or process.  Any final judgment which is not appealed or
appealable and may be entered in any such action or proceeding shall be binding
and conclusive on the parties hereto and all persons having or claiming to have
any interest in this Plan.  To the extent permitted by law, if a legal action is
begun against the Company, its officers or employees, the Committee, or the
Trustee by or on behalf of any person and such action results adversely to such
person or if a legal action arises because of conflicting claims to a
Participant's or other person's benefits, the costs to such person of defending
the action will be charged to the amounts, if any, which were involved in the
action or were payable to the Participant or other person concerned.  To the
extent permitted by applicable law, acceptance of participation in this Plan
shall constitute a release of the Company, its officers, employees and agents,
and the Committee from any and all liability and obligation not involving
willful misconduct or gross neglect.

     5.6  Cooperation.  As a condition of participation under the Plan, each
          -----------
Participant agrees to cooperate in providing all information required to carry
out the Plan, including taking such physical examination and providing such
medical history as may be required to obtain insurance with respect to such
Participant.

                                      -8-
<PAGE>

     5.7  Severability.  In the event any provision of the Plan shall be held
          ------------
invalid or illegal for any reason, such illegality or invalidity shall not
affect the remaining parts of the Plan, but the Plan shall be construed and
enforced as if the illegal or invalid provision had never been inserted, and the
Company shall have the privilege and opportunity to correct and remedy such
questions of illegality or invalidity by amendment as provided in the Plan.

     5.8  Applicable Law.  This Plan shall be governed and construed in
          --------------
accordance with the laws of the State of North Carolina.

                                 Article VII.
                                 -----------
                          Amendment and Termination.
                          -------------------------

     The Company reserves the right to amend or terminate the Plan at any time
by resolution of the Board of Directors or by action by any person or persons
authorized by resolution of the Board, provided such amendment or termination
shall not operate to reduce the amount of benefits accrued by any Participant as
of the date of the amendment or termination.  Upon termination of the Plan, the
Board may, but shall not be required to, provide for the payment of the
actuarial equivalent of the vested benefit of some or all of the Participants in
a single lump sum payment.  The fact that one or more Participants is found to
be ineligible to participate in the Plan as a result of rules or regulations
promulgated under ERISA or by the Department of Labor shall not in itself cause
a termination of the Plan.

                                      -9-
<PAGE>

     IN WITNESS WHEREOF, the Company has caused this instrument to be executed
by its duly authorized officers on this 1st day of May, 1999, effective as of
May 1, 1999.
                                   KEWAUNEE SCIENTIFIC CORPORATION


                                   By: /s/ James J. Rossi
                                       ----------------------------------
                                   Its: Vice President of Human Resources


ATTEST:

By  /s/ D. M. Parker
    --------------------------

Its Vice President - Finance

                                      -10-
<PAGE>

                                  Exhibit A.
                                  ---------
                         List of Initial Participants.
                         ----------------------------

1.   Ron Gewin

2.   Eli Manchester, Jr.

3.   Mike Parker

4.   Kurt Rindoks

5.   Bill Shumaker

                                      -11-
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.42A
<SEQUENCE>3
<FILENAME>0003.txt
<DESCRIPTION>FIRST AMENDMENT PENSION EQUALIZATION PLAN
<TEXT>

<PAGE>

                                                                          10.42a

                              FIRST AMENDMENT TO
                        KEWAUNEE SCIENTIFIC CORPORATION
                           PENSION EQUALIZATION PLAN
                            (Effective May 1, 1999)

     The Kewaunee Scientific Corporation Pension Equalization Plan (the "Plan"),
as established effective May 1, 1999, is hereby amended this 27th day of May,
1999, effective as of the original effective date of the Plan, as follows:

     1.   Section 5.4 of the Plan is amended to read as follows:

     "5.4 Funding.  The Company shall make payment of its contributions under
          -------
the Plan to the Company's Irrevocable Grantor Trust, which was originally
established in connection with the establishment of the Company's Executive
Deferred Compensation Plan, and which is being amended contemporaneously with
the establishment of this Plan to accept contributions under this Plan in
addition to contributions under the Executive Deferred Compensation Plan.  Such
contributions shall be made, either in cash or by the delivery to the trustee
thereunder of insurance contracts, in such amounts as the Company shall
reasonably decide are necessary to provide for all benefits payable under the
Plan, subject to the provisions of the Trust Agreement establishing the
Irrevocable Grantor Trust with respect to required contributions in the event of
a Potential Change in Control (as defined therein).  The Company may establish a
separate trust for the accumulation and investment of all or part of the
contributions under this Plan, in which event the term Irrevocable Grantor Trust
shall also include such separate trust.  The Company shall have the right to
appoint and remove trustees of the Irrevocable Grantor Trust and to amend the
trust agreement governing the Irrevocable Grantor Trust, subject to the terms
thereof.  The establishment and funding of the Irrevocable Grantor Trust shall
not relieve the Company of its obligations under this Plan, but any amount
actually paid by the Irrevocable Grantor Trust to a Participant or beneficiary
shall be credited against the amount owed by the Company to such
<PAGE>

Participant or beneficiary under the Plan. No employee shall have any right,
title, or interest whatever in or to any insurance contracts, investment
reserves, accounts, funds or grantor trusts that the Company may purchase,
establish, or accumulate to aid in providing the benefits under this Plan.
Neither an employee nor a beneficiary of an employee shall acquire any interest
greater than that of an unsecured creditor of the Company. Any assets of the
Company or of any trust or other fund of the Company from which Plan benefits
may be paid shall remain in all respects assets of the Company until payments of
such benefits are actually made. Nothing contained in this Plan, and no action
taken pursuant to its provisions, shall create a trust or fiduciary relationship
of any kind between the Company and an employee or any other person."

     2.   In all other respects, the Plan shall remain in full force and effect.

     IN WITNESS WHEREOF, the Company has caused this Fourth Amendment to be
executed by its duly authorized officers on the date and year first above
written.


                              KEWAUNEE SCIENTIFIC CORPORATION



                              By: /s/ James J. Rossi
                                 ---------------------------------------
                                  Its: Vice President of Human Resources

                                      -2-
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.43
<SEQUENCE>4
<FILENAME>0004.txt
<DESCRIPTION>FISCAL YEAR 2001 INCENTIVE PLAN
<TEXT>

<PAGE>

                                                                           10.43

                        KEWAUNEE SCIENTIFIC CORPORATION
                               FISCAL YEAR 2001
                             INCENTIVE BONUS PLAN


The Fiscal Year 2001 Incentive Bonus Plan (the Plan) will provide for a bonus
pool and bonus payouts based upon achievement of various levels of pre-tax
earnings (after bonus accruals) for the year and other conditions described
herein, as approved by the Company's Board of Directors.  The Plan is proposed
as a one-year plan for Fiscal Year 2001.

The provisions of the Plan are:

1.   Eligibility of Participants to Share in the Bonus Pool
     ------------------------------------------------------

     a.   Eligible participants of the Plan will be nominated by the President
          and approved by the Board of Directors, upon recommendation by the
          Compensation Committee. The bonus potential percentages for each
          participant in the Plan will also be approved by the Board of
          Directors, upon recommendation by the Compensation Committee.

     b.   Each participant will be eligible to share in the pool up to the
          specified percentage of his or her May 1, 2000 base salary.

     c.   In addition to individuals reporting directly to the President,
          managers fulfilling the following criteria are eligible to participate
          in the Plan:

          1.   Salary Grade 14 or above;
          2.   Seniority of one year or more;
          3.   Is not currently in another incentive plan (e.g., sales plan);
          4.   Is a direct report to a direct report to the President; or
          5.   Is a manager recommended by the President.

     d.   Participants in the Plan and their applicable bonus potential amounts
          are shown on Exhibits II through V to the Company's FY 2001 Bonus
          Schedules (all Exhibits referred to in this Plan are exhibits to such
          Schedules).

2.   Building of a Bonus Pool
     ------------------------

     a.   Division Pools
          --------------

          .    The divisions (the Laboratory Products Group and the Technical
               Products Group) will start to accrue pools for potential bonus
               payouts once pre-tax operating earnings of each division reach
               the amounts shown as Goal 1 on Exhibits II, III and IV, and
               maximum incentive bonus payouts will be accrued and available for
               payout based upon the guidelines shown on those exhibits.

                                       1
<PAGE>

     b.   Non-divisional Corporate Pool
          -----------------------------

          .    A pool will start accumulating once pre-tax earnings reach the
               amounts shown on Exhibit V, and maximum bonus payouts will be
               accrued and available for payout based upon the guidelines shown
               on that exhibit.

3.   Bonus Payout Conditions
     -----------------------

          .    If the Company achieves pre-tax earnings less than the amount
               shown as Goal 1 on Exhibit V, no awards will be paid to any non-
               divisional corporate employee, except at the discretion of the
               Board of Directors, upon recommendation by the Compensation
               Committee.

          .    If a division achieves pre-tax earnings less than the amounts
               shown for it as Goal 1 on Exhibits II, III or IV, no awards will
               be paid to its employees except at the discretion of the Board of
               Directors, upon recommendation by the Compensation Committee.

          .    All division participants will earn their awards dependent on
               their division's performance and their individual MBO
               performance.

          .    Beginning with the achievement of Goal 1, the bonus potential
               percentage for each participant is linear between each goal with
               the corresponding increase in pre-tax earnings, up to the
               individual's maximum bonus potential percentage.

          .    Positive or negative financial adjustments outside the control of
               management (such as, but not limited to, proceeds from insurance
               claims, gains or losses from the sale of capital assets, adoption
               of new generally accepted accounting pronouncements, etc.) will
               be assessed by the Board of Directors and the pre-tax earnings
               under the Plan may be adjusted for these items.

          .    Any portion of the bonus pool not awarded to participants will be
               retained by the Company.

          .    If a participant transfers between performance entities during
               the year, his or her incentive compensation will be based on the
               performance of the respective entities on a pro rata basis from
               his or her transfer date as determined by the President.

                                       2
<PAGE>

          .    A participant must be an employee of the Company on the last day
               of the plan year (April 30) to be eligible to receive a bonus. In
               unusual circumstances, however, the Board of Directors, upon
               recommendation by the Compensation Committee, may grant a
               discretionary bonus.

          .    The Board of Directors, upon recommendation by the Compensation
               Committee, may approve the pro rata participation of a
               participant who joins the Company or who is appointed to a key
               position within the Company after the outset of the Plan year,
               with a pro rata increase in the bonus pool.

4.   Participant's Bonus Potential
     -----------------------------

     Each participant's bonus potential will be comprised of the following:

          .    A Fixed Bonus equal to 75% of each participant's bonus potential
               will be based on achievement of corporate or divisional pre-tax
               earnings goals, as set forth in the Plan, and

          .    A Discretionary Bonus up to the remaining 25% of each
               participant's bonus potential will be calculated, taking into
               account the participant's MBO achievements and other relevant
               factors during the year. The discretionary portion of each
               participant's bonus will take into account the participant's
               achievement of management goals established, and weighted, in
               July 2000, and approved by the President. The degree of
               achievement of these goals will be recommended by each
               participant's manager immediately subsequent to April 30, 2001,
               and the discretionary bonus, if any, will then be determined and
               awarded at the discretion of the Board of Directors, upon
               recommendation by the President and the Compensation Committee.

5.   The Plan may be amended at any time by the Board of Directors.

                                       3
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13
<SEQUENCE>5
<FILENAME>0005.txt
<DESCRIPTION>ANNUAL REPORTS TO SHAREHOLDERS
<TEXT>

<PAGE>

                   [LOGO OF KEWAUNEE SCIENTIFIC CORPORATION]

Fume Hoods



Wood Cabinetry



Computer Enclosures                       World of



Steel Cabinetry                           [GRAPHIC]



Laboratory Furniture                      Merging
                                          Markets...


Worksurfaces



Mobile Carts



LAN Workstations



Modular Furniture                                             2000 ANNUAL REPORT
<PAGE>

- --------------------------------------------------------------------------------
CORPORATE PROFILE
- --------------------------------------------------------------------------------

Kewaunee Scientific Corporation is a recognized leader in the design,
manufacture, and installation of scientific and technical furniture. The
Company's Corporate headquarters are located in Statesville, North Carolina. The
manufacturing facilities located in Statesville, produce steel and wood
laboratory furniture, fume hoods, network storage systems, and worksurfaces. The
manufacturing facility located in Lockhart, Texas, produces technical furniture,
including workstations, workbenches, computer enclosures, and related
accessories, all to support local area computer networks and for the storage and
assembly of computers and light electronics.

                             ...Flexibility is our Greatest Asset

                                   [GRAPHIC]
<PAGE>

- --------------------------------------------------------------------------------
FINANCIAL HIGHLIGHTS
- --------------------------------------------------------------------------------
                                                 Kewaunee Scientific Corporation
<TABLE>
<CAPTION>

$ in thousands, except per share data           2000         1999      Percent Change
- -------------------------------------------------------------------------------------
<S>                                           <C>           <C>        <C>
Operating Data:

Net sales                                     $74,798       $77,478       -3.5
- -------------------------------------------------------------------------------------
Gross profit                                  $17,083       $17,696       -3.5
- -------------------------------------------------------------------------------------
Operating expenses                            $12,429       $12,315       +0.9
- -------------------------------------------------------------------------------------
Operating earnings                            $ 4,654       $ 5,381      -13.5
- -------------------------------------------------------------------------------------
Net earnings                                  $ 3,561       $ 3,396       +4.9
- -------------------------------------------------------------------------------------
Net earnings per share
  Basic                                       $  1.45       $  1.40       +3.6
  Diluted                                     $  1.44       $  1.38       +4.3
- -------------------------------------------------------------------------------------
Return on average equity                        15.1%         16.5%         --
- -------------------------------------------------------------------------------------
Cash dividends per share                      $  0.26       $  0.22      +18.2
- -------------------------------------------------------------------------------------

<CAPTION>


Year-End Data:

Net working capital                           $11,472       $10,159      +12.9
- -------------------------------------------------------------------------------------
Total borrowings/long-term debt               $ 2,555       $   939     +172.1
- -------------------------------------------------------------------------------------
Stockholders' equity                          $25,135       $22,032      +14.1
- -------------------------------------------------------------------------------------
Book value per share                          $ 10.19       $  9.04      +12.7
- -------------------------------------------------------------------------------------
Closing market price per share                $13.438       $10.125      +32.7
- -------------------------------------------------------------------------------------
</TABLE>

- --------------------------------------------------------------------------------
TABLE OF CONTENTS
- --------------------------------------------------------------------------------

        2       Letter to our Stockholders
        4       Markets/Products
        8       Forward Looking Statement Disclosure
        8       Management's Discussion and Analysis
       10       Financial Statements and Notes
       20       Reports of Independent Accountants and Management
       21       Summary of Selected Financial Data
       22       Quarterly Financial Data
       23       Corporate Information

                                                                          Page 1
<PAGE>

- --------------------------------------------------------------------------------
LETTER TO OUR STOCKHOLDERS
- --------------------------------------------------------------------------------

We are delighted to provide to you our report on the Company for fiscal year
2000, as we completed our 94th year of business with record net earnings.

Net earnings for the year increased to $3,561,000, or $1.44 per diluted share,
up 4.9% from net earnings of $3,396,000, or $1.38 per diluted share in the prior
year. Earnings for the year benefited from strong sales of technical furniture
products, increased sales of laboratory products to educational customers, and a
lower effective tax rate. Tax credits, including credits earned in prior years,
decreased our tax rate for the year and increased net earnings by $410,000, or
$.17 per diluted share.

Sales for the year were $74,798,000, a decrease of 3.5% from sales of
$77,478,000 in the prior year. Sales of technical furniture products surged
33.3% during the year to $13,120,000, as we experienced significant growth in
sales of these products to the technology and internet markets. Sales of
laboratory products decreased 8.8% to $61,678,000 during the year, as the
industrial research market for laboratory products softened, particularly in the
second half of the year, while sales to the educational market increased.

Capital investments during the year were $3.4 million, bringing our total
expenditures for the past two years to $7.0 million. The continuing
modernization of our Statesville factories during the year provided significant
improvements in manufacturing efficiencies and product quality, as well as
reducing manufacturing costs and increasing manufacturing capacity. These
factors were very helpful in our winning several important orders during the
fourth quarter and are allowing us to enter new markets of opportunity. The
Company's unfilled sales order backlog increased to $31.5 million at year-end,
up from $27.0 million at April 30, 1999.

We continue to concentrate on the introduction of new products. Several new
technical furniture products introduced during the year, including an innovative
network storage system for hardware components used by the internet and
telecommunications markets, have been well received in the marketplace. We
believe these products have the potential to favorably impact future earnings.

A new energy-efficient Dynamic Barrier fume hood introduced late in the year is
enjoying good market acceptance. This fume hood requires over 70% less exhaust
air volume than a traditional by-pass fume hood, providing significant savings
to the customer on annual energy consumption.

The Company's financial strength continued to improve during the year. We
finished the year with working capital of $11,472,000, up from $10,159,000 at
the end of last year. Stockholders' equity increased during the year to
$25,135,000 at year-end, resulting in a book value per share of $10.19. Our only
borrowings at the end of the year were $2,555,000 in short-term debt.

Page 2
<PAGE>

                                    [PHOTO]

                 Corporate Executive Officers (left to right):
  James J. Rossi, Eli Manchester, Jr., D. Michael Parker, William A. Shumaker,
                                 Kurt P. Rindoks

Outlook
Kewaunee's prospects for the future are very encouraging. We are particularly
excited about the potential for our technical products that serve the
rapidly-expanding high tech and computer markets. To capitalize on these
opportunities, we will continue to seek strategic relationships with customers
and develop distribution channels that will best serve this marketplace.

We think the future will provide opportunities for growth in sales of laboratory
casework, fume hoods, and worksurfaces. Demand for these products in the
educational marketplace is expected to continue to increase, as projected rising
student enrollments should continue to boost new school construction for many
years. The industrial research market, including the biotechnology and
pharmaceutical industries, continues to provide the largest opportunity for
sales of our laboratory products, despite the current softness in this market.

Ongoing support and contributions of our associates, our dealers and direct
sales representatives, our national stocking distributor of laboratory products
- - VWR Scientific Products, and our stockholders are essential to our continued
growth and success. To each and all of these groups, we are especially grateful.

Sincerely,

/s/ Eli Manchester, Jr.           /s/ William A. Shumaker

Eli Manchester, Jr.               William A. Shumaker
Chairman,                         President,
Chief Executive Officer           Chief Operating Officer

July, 2000

                                                                          Page 3
<PAGE>

- --------------------------------------------------------------------------------
LABORATORY PRODUCTS
- --------------------------------------------------------------------------------

Kewaunee provides innovative products and services to highly respected clients
in several major markets:

 . Pharmaceutical and Biotechnology
 . Industrial and Chemical
 . University and Secondary Education
 . Health Care and Government
 . International

Our extensive product offering is designed with flexibility to meet the
sophisticated demands of any laboratory environment. Utilized individually or in
combination, our casework and fume hood offerings are engineered specifically
for strength, durability, and variety of function. Kewaunee sets the standard in
providing products and services to meet the unique requirements of a diverse
customer base.

                                   [GRAPHIC]

- --------------------------------------------------------------------------------
Pharmaceutical and Biotechnology
- --------------------------------------------------------------------------------

The backbone of the Pharmaceutical and Biotechnology industries is research and
development. All of Kewaunee's standard product lines are specifically designed
for these markets and include the Research Collection of steel casework; Alpha
System of flexible furniture; Supreme Air fume hoods; and Kemresin and Kemresin
Lite worksurfaces. In addition, our Signature Series wood casework is being
increasingly specified in these industries, exemplifying a trend toward merging
markets.

Kewaunee designs, engineers, and manufactures customized components for clients
such as G.D. Searle, Abbott Laboratories, Merck, and Glaxo Wellcome. Our
recently introduced, energy conservation Dynamic Barrier fume hood incorporates
features that will be beneficial for the type of research these companies
conduct.

                                   [GRAPHIC]

Page 4
<PAGE>

- --------------------------------------------------------------------------------
Industrial and Chemical
- --------------------------------------------------------------------------------

Air Products, Rohm & Haas, Estee Lauder, Eveready, Proctor & Gamble, and
Westinghouse are a few of the major Industrial and Chemical clients who specify
Kewaunee. These companies develop and manufacture products consumers use every
day. Whether we are furnishing a single Alpha Mobile Cart or a two-story custom
fume hood, Kewaunee offers optimum solutions. And, when the client specifies a
renewable worksurface, our exclusive Kemresin Lite products can be provided
without sacrificing acid resistance.

                                   [GRAPHIC]

- --------------------------------------------------------------------------------
University and Secondary Education
- --------------------------------------------------------------------------------

North to South, East to West, from the Ivy League of Yale, Princeton, and MIT ,
the prestigious Southern universities of Duke and Emory, the Midwest campuses of
Illinois and Indiana to the West Coast powerhouses of Stanford, Cal Tech and
UCLA, Kewaunee laboratory environments stimulate learning. Both the University
and Secondary Education markets are experiencing a construction boom to support
the rising student population, and the growing availability of R & D funding
opportunities. These factors are driving a growth in Kewaunee's wood laboratory
casework projects.

                                   [GRAPHIC]

                                                                          Page 5
<PAGE>

- --------------------------------------------------------------------------------
Health Care and Government
- --------------------------------------------------------------------------------

The diverse group of clients who comprise the Health Care and Government markets
ranges from hospitals, crime labs, museums, the military, wastewater treatment
facilities, and even the U. S. Mint.

Many health care research facilities, including Fred Hutchinson Cancer Care
Alliance and the National Cancer Institute, along with national medical centers
such as Children's Hospital, Harvard Medical School Hospital, and The Lied
Transplant Center, select Kewaunee for their major laboratory furniture
purchases. FDA, EPA, DOE, the military, Smithsonian Institution, and NASA
conduct research that demands the quality and safety features we build into
every Kewaunee product.

                                   [GRAPHIC]

- --------------------------------------------------------------------------------
International
- --------------------------------------------------------------------------------

Kewaunee expanded its international presence in fiscal year 2000 through new
representation in the United Arab Emirates and Brazil, along with the continued
success of our joint venture dealership in Singapore. International clients
include well known multi-national corporations such as Amoco, Exxon, 3M,
Schering-Plough, Dupont, Siemens, Shell, and Witco. We also completed a
multi-story laboratory project for the Singapore National Cancer Centre, which
featured our flexible Alpha System and Kemresin Lite worksurfaces.

                                   [GRAPHIC]


Page 6
<PAGE>

- --------------------------------------------------------------------------------
TECHNICAL PRODUCTS
- --------------------------------------------------------------------------------

Kewaunee's technical products are sold to customers in the high tech and
computer markets including:

  . Engineering and Ergonomics
  . High Tech Electronics R & D and Manufacturing
  . Computer Network and Internet Infrastructure
    (LAN/WAN/Internet)
  . Telecommunications Network Centers

Our flexibility for rapid product development is a core compatibility that
allows customization of modular workstations and computer enclosures to meet
exact customer needs.

                                   [GRAPHIC]

- --------------------------------------------------------------------------------
Engineering and Ergonomics
- --------------------------------------------------------------------------------

The products of the technology revolution, in many instances, are designed,
engineered, and tested on the Sturdilite product line. The ample storage
options, electrostatic dissipating capabilities, and high quality find favor in
organizations such as Motorola, Hewlett-Packard, Lockheed Martin, NASA, FEMA,
Westinghouse, and Siemens--customers who demand discriminating value. Within the
high tech manufacturing sector, the Evolution line and new ADJUSTAbench combine
with responsive lead times and attention to ergonomic issues. These appeal to
customers such as Nokia, IBM, Boeing, GTE, Gateway, Mattel, Corning, and
Panasonic/Matsushita.

- --------------------------------------------------------------------------------
LAN/WAN/Internet
- --------------------------------------------------------------------------------

In addition to creating productive solutions for the manufacturers of high tech
equipment, Kewaunee also provides furniture, enclosures, and storage systems for
the end users of that equipment.

The Evolution for LANs product line helps companies organize and create flexible
storage solutions for the technology driving their business growth. Applications
for this modular approach of supporting computer servers, network monitoring and
switching componentry gives us a diverse customer base including Mellon USA
Leasing, Excel Switching, Xerox, Gillette, Circuit City, and FedEx.

                                   [GRAPHIC]

                                                                          Page 7
<PAGE>

- --------------------------------------------------------------------------------
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
- --------------------------------------------------------------------------------

Certain statements in this annual report, including the Letter to Stockholders,
narrative text, captions and Management's Discussion and Analysis of Financial
Condition and Results of Operations, constitute "forward-looking" statements
within the meaning of the Private Securities Litigation Reform Act of 1995 (the
"Reform Act"). Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that could significantly impact results or
achievements expressed or implied by such forward-looking statements. These
factors include, but are not limited to, economic, competitive, governmental,
and technological factors, affecting the Company's operations, markets,
products, services, and prices. The cautionary statements made pursuant to the
Reform Act herein and elsewhere by the Company should not be construed as
exhaustive or as any admission regarding the adequacy of disclosures made by the
Company prior to the effective date of the Reform Act. The Company cannot always
predict what factors would cause actual results to differ materially from those
indicated by the forward-looking statements. In addition, readers are urged to
consider statements that include the terms "believes," "belief," "expects,"
"plans," "objectives," "anticipates," "intends," or the like to be uncertain and
forward-looking.

- --------------------------------------------------------------------------------
MANAGEMENT'S DISCUSSION AND ANALYSIS
- --------------------------------------------------------------------------------

Results of Operations

Sales for fiscal year 2000 were $74.8 million, down 3.5% from fiscal year 1999
sales of $77.5 million. Sales were adversely affected by a softer industrial
research market for laboratory products. The impact of the lower sales in this
market was partially offset by strong sales of technical furniture and increased
sales of laboratory products to educational customers. Sales for fiscal year
1999 increased 6.1% from fiscal year 1998 sales of $73.0 million. The sales
increase for the 1999 fiscal year resulted primarily from increased sales of
laboratory products, partially offset by lower sales of technical furniture. The
Company's unfilled sales order backlog increased to $31.5 million at April 30,
2000, up from $27.0 million at April 30, 1999, and $24.9 million at April 30,
1998.

Gross profit represented 22.8%, 22.8%, and 23.9% of sales in fiscal years 2000,
1999, and 1998, respectively. The gross profit margin in fiscal year 2000 was
favorably affected by improved manufacturing efficiencies and reduced
manufacturing costs at the Company's Statesville facility, as well as increased
sales of technical furniture.

The impact of these factors was offset by lower sales volumes and a change in
the product sales mix of laboratory products. As compared to fiscal year 1998,
the gross profit margin in fiscal year 1999 was unfavorably affected by start-up
costs associated with several new products, a weaker technical furniture
marketplace, and a change in the overall product sales mix.

Operating expenses were $12.4 million, $12.3 million, and $13.1 million in
fiscal years 2000, 1999, and 1998, respectively, and 16.6%, 15.9%, and 17.9% of
sales, respectively. The modest increase in operating expenses in fiscal year
2000 was primarily attributable to inflationary factors. The decline in
operating expenses in fiscal year 1999 resulted primarily from a reduction in
sales commissions, and to a lesser extent, reductions in bad debt expense, legal
costs, and other administrative costs.

Other income was $326,000, $325,000, and $45,000 in fiscal years 2000, 1999, and
1998, respectively. Other income in fiscal years 2000 and 1999 included income
of $244,000 and $295,000, respectively, from collections associated with a
litigation settlement with certain

Page 8
<PAGE>

suppliers for overcharges in earlier years. Interest expense was $169,000,
$96,000, and $149,000 in fiscal years 2000, 1999, and 1998, respectively. The
change in interest expense for fiscal years 2000 and 1999 resulted primarily
from changes in the levels of borrowings during each year.

The Company recorded income tax expense of $1.3 million, or 26.0% of pretax
earnings, in fiscal year 2000, as compared to an effective tax rate of 39.5% in
fiscal years 1999 and 1998. The fiscal year 2000 effective tax rate was reduced
by federal and state tax credits for research and development activities, as
well as state tax credits available for purchases of machinery and equipment.
The Company recorded income tax expense of $2.2 million and $1.7 million in
fiscal years 1999 and 1998, respectively.

Net earnings increased to $3.6 million, or $1.44 per diluted share, in fiscal
year 2000, from $3.4 million, or $1.38 per diluted share, in fiscal year 1999.
Net earnings were $2.6 million, or $1.06 per diluted share, in fiscal year 1998.

Liquidity and Capital Resources
The Company's principal sources of liquidity have been funds generated from
operating activities, supplemented as needed by the Company's credit facility.
The Company believes that these sources will be sufficient to support ongoing
business levels, including capital expenditures.

Operating activities provided cash of $2.2 million, $1.3 million, and $3.4
million in fiscal years 2000, 1999, and 1998, respectively, primarily from
earnings in each of these years. Working capital increased to $11.5 million at
April 30, 2000, from $10.2 million at April 30, 1999, and the ratio of current
assets to current liabilities increased to 2.0-to-1 at April 30, 2000 from
1.9-to-1 at April 30, 1999.

The Company has a credit facility with a bank that allows the Company to borrow
up to $3 million under a two-year unsecured revolving credit component and up to
$5 million under a seven-year equipment loan component. At April 30, 2000,
advances of $2,555,000 were outstanding under the revolving credit loan. No
advances were outstanding under the equipment loan component.

Capital expenditures of $3.4 million, $3.7 million, and $1.5 million in fiscal
years 2000, 1999, and 1998, respectively, were primarily funded by cash provided
by operating activities. Fiscal year 2001 capital expenditures are not expected
to differ significantly from expenditures in the two previous years and are
expected to be funded primarily by operating activities.

The Company paid cash dividends of $.26 per share, $.22 per share, and $.18 per
share in fiscal years 2000, 1999, and 1998, respectively. In the third quarter
of fiscal year 2000, the Company increased its quarterly cash dividend to seven
cents per share from six cents per share. The Company expects to pay dividends
in the future in line with the Company's actual and anticipated future operating
results.

Year 2000
The Company did not experience any significant disruption to its operations
related to computer system programming failures or errors, either internally or
with its customers or vendors, associated with the year 2000 issue. The
Company's expenditures related to Y2K compliance were less than $100,000 and
were expensed as incurred.

Recent Accounting Standards
In June 1998, the Financial Accounting Standards Board ("FASB") issued Statement
of Financial Accounting Standards ("SFAS") No. 133, "Accounting for Derivative
Instruments and Hedging Activities," which establishes new standards of
accounting and reporting for derivative instruments and hedging activities. In
June 1999 the FASB issued SFAS No. 137, which deferred the effective date of
adoption of SFAS No. 133 to June 15, 2000. The Company will adopt SFAS No. 133
in the first fiscal quarter of 2001 and does not expect the adoption to have a
material effect on its financial condition or results of operations.

                                                                          Page 9
<PAGE>

- --------------------------------------------------------------------------------
STATEMENTS OF OPERATIONS
- --------------------------------------------------------------------------------
Years Ended April 30                            Kewaunee Scientific Corporation

<TABLE>
<CAPTION>

$ and shares in thousands, except per share data       2000           1999           1998
- --------------------------------------------------------------------------------------------
<S>                                                  <C>            <C>            <C>
Net sales                                            $ 74,798       $ 77,478       $ 73,037
Costs of products sold                                 57,715         59,782         55,600
- --------------------------------------------------------------------------------------------
Gross profit                                           17,083         17,696         17,437
Operating expenses                                     12,429         12,315         13,096
- --------------------------------------------------------------------------------------------
Operating earnings                                      4,654          5,381          4,341
Other income, net                                         326            325             45
Interest expense                                         (169)           (96)          (149)
- --------------------------------------------------------------------------------------------
Earnings before income taxes                            4,811          5,610          4,237
Income tax expense                                      1,250          2,214          1,674
- --------------------------------------------------------------------------------------------
Net earnings                                         $  3,561       $  3,396       $  2,563
- --------------------------------------------------------------------------------------------
Net earnings per share
        Basic                                        $   1.45       $   1.40       $   1.07
        Diluted                                      $   1.44       $   1.38       $   1.06
- --------------------------------------------------------------------------------------------
Weighted average number of
common shares outstanding
        Basic                                           2,456          2,432          2,386
        Diluted                                         2,478          2,464          2,423
- --------------------------------------------------------------------------------------------
</TABLE>

- --------------------------------------------------------------------------------
STATEMENTS OF STOCKHOLDERS' EQUITY
- --------------------------------------------------------------------------------
Years Ended April 30                            Kewaunee Scientific Corporation

<TABLE>
<CAPTION>
 $ in thousands,                            Common       Additional       Retained    Treasury   Total Stockholders'
 except per share data                       Stock     Paid-in Capital    Earnings      Stock          Equity
- --------------------------------------------------------------------------------------------------------------------
<S>                                       <C>          <C>                <C>        <C>         <C>
Balance at April 30, 1997                 $  6,550        $    116        $ 11,435   $ (1,515)        $ 16,586
Net Earnings                                    --              --           2,563         --            2,563
Cash dividends declared, $.18 per share         --              --            (430)        --             (430)
Stock options exercised, 48,875 shares          --              28              --        292              320
- --------------------------------------------------------------------------------------------------------------------
Balance at April 30, 1998                    6,550             144          13,568     (1,223)          19,039
- --------------------------------------------------------------------------------------------------------------------
Net Earnings                                    --              --           3,396         --            3,396
Cash dividends declared, $.22 per share         --              --            (535)        --             (535)
Stock options exercised, 21,500 shares          --               4              --        128              132
- --------------------------------------------------------------------------------------------------------------------
Balance at April 30, 1999                    6,550             148          16,429     (1,095)          22,032
- --------------------------------------------------------------------------------------------------------------------
Net earnings                                    --              --           3,561         --            3,561
Cash dividends declared, $.26 per share         --              --            (639)        --             (639)
Stock options exercised, 29,875 shares          --               6              --        178              184
Purchase of treasury stock, 300 shares          --              --              --         (3)              (3)
- --------------------------------------------------------------------------------------------------------------------
Balance at April 30, 2000                 $  6,550        $    154        $ 19,351   $   (920)        $ 25,135
- --------------------------------------------------------------------------------------------------------------------
</TABLE>

       The accompanying Notes are an integral part of these Financial Statements

Page 10
<PAGE>

- --------------------------------------------------------------------------------
BALANCE SHEETS
- --------------------------------------------------------------------------------
April 30                                        Kewaunee Scientific Corporation

ASSETS  $ and shares in thousands, except per share data     2000         1999
- --------------------------------------------------------------------------------
Current Assets
Cash and cash equivalents                                  $     9      $     8
Receivables, less allowance
    $490 (2000); $387 (1999)                                17,993       17,231
Inventories                                                  3,499        2,940
Deferred income taxes                                        1,151        1,026
Prepaid expenses and other current assets                      380          626
- --------------------------------------------------------------------------------
Total Current Assets                                        23,032       21,831
- --------------------------------------------------------------------------------
Property, Plant and Equipment
Land                                                           109          109
Buildings and improvements                                  13,846       13,556
Machinery and equipment                                     19,287       16,637
- --------------------------------------------------------------------------------
Property, plant and equipment                               33,242       30,302
Accumulated depreciation                                   (19,736)     (18,177)
- --------------------------------------------------------------------------------
Net Property, Plant and Equipment                           13,506       12,125
- --------------------------------------------------------------------------------
Other Assets                                                 2,778        2,079
- --------------------------------------------------------------------------------
Total Assets                                              $ 39,316     $ 36,035
================================================================================

LIABILITIES AND STOCKHOLDERS' EQUITY
- --------------------------------------------------------------------------------
Current Liabilities
Short-term borrowings                                     $  2,555     $    939
Accounts payable                                             5,412        6,566
Employee compensation and amounts withheld                   1,352        1,973
Other accrued expenses                                       2,241        2,194
- --------------------------------------------------------------------------------
Total Current Liabilities                                   11,560       11,672
- --------------------------------------------------------------------------------
Deferred Income Taxes                                          944        1,074
Accrued Employee Benefit Plan Costs                          1,677        1,257
- --------------------------------------------------------------------------------
Total Liabilities                                           14,181       14,003
- --------------------------------------------------------------------------------
Commitments and Contingencies (Note 6)
Stockholders' Equity
Common stock, $2.50 par value
    Authorized-5,000 shares; Issued-2,620 shares             6,550        6,550
Additional paid-in-capital                                     154          148
Retained earnings                                           19,351       16,429
Common stock in treasury, at cost
    154 shares (2000); 184 (1999)                             (920)      (1,095)
- --------------------------------------------------------------------------------
Total Stockholders' Equity                                  25,135       22,032
- --------------------------------------------------------------------------------
Total Liabilities and Stockholders' Equity                $ 39,316     $ 36,035
================================================================================
       The accompanying Notes are an integral part of these Financial Statements

                                                                         Page 11
<PAGE>

- --------------------------------------------------------------------------------
STATEMENTS OF CASH FLOWS
- --------------------------------------------------------------------------------
Years Ended April 30                            Kewaunee Scientific Corporation

<TABLE>
<CAPTION>
$ in thousands                                         2000        1999      1998
- ------------------------------------------------------------------------------------
<S>                                                   <C>        <C>        <C>
Cash Flows from Operating Activities
Net earnings                                          $ 3,561    $ 3,396    $ 2,563
Adjustments to reconcile net earnings to net
 cash provided by operating activities:
    Depreciation                                        1,968      1,565      1,312
    Bad debt provision                                    123         16        301
    Deferred income tax expense (benefit)                (255)       479        316
    Increase in receivables                              (885)    (3,428)    (1,253)
    Decrease (increase) in inventories                   (559)       770     (1,764)
    (Decrease) increase in accounts payables
      and accrued expenses                             (1,728)      (554)     1,115
    Other, net                                            (30)      (903)       843
- ------------------------------------------------------------------------------------
Net cash provided by operating activities               2,195      1,341      3,433
- ------------------------------------------------------------------------------------
Cash Flows from Investing Activities
Capital expenditures                                   (3,352)    (3,678)    (1,520)
- ------------------------------------------------------------------------------------
Net cash used in investing activities                  (3,352)    (3,678)    (1,520)
- ------------------------------------------------------------------------------------
Cash Flows from Financing Activities
Dividends paid                                           (639)      (535)      (430)
Net increase in short-term borrowings                   1,616        939       --
Proceeds from exercise of stock options
  (including tax benefit)                                 184        132        320
Purchase of treasury stock                                 (3)      --         --
- ------------------------------------------------------------------------------------
Net cash provided by (used in) financing activities     1,158        536       (110)
- ------------------------------------------------------------------------------------
Increase (Decrease) in Cash and Cash Equivalents            1     (1,801)     1,803
Cash and Cash Equivalents at Beginning of Year              8      1,809          6
- ------------------------------------------------------------------------------------
Cash and Cash Equivalents at End of Year              $     9    $     8    $ 1,809
- ------------------------------------------------------------------------------------
Supplemental Disclosure of Cash Flow Information
    Interest paid                                     $   159    $    82    $   144
    Income taxes paid                                 $ 1,080    $ 2,321    $ 1,518
====================================================================================
</TABLE>

       The accompanying Notes are an integral part of these Financial Statements

Page 12
<PAGE>

- --------------------------------------------------------------------------------
NOTES TO FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------

Note 1--Summary of Significant Accounting Policies

Kewaunee Scientific Corporation (the "Company") is a manufacturer of scientific
and technical furniture, including wood and steel laboratory furniture, fume
hoods, network storage systems, worksurfaces, workstations, workbenches,
computer enclosures, and other related accessories. Sales are made through
purchase orders and contracts submitted by customers, the Company's dealers and
agents, a national distributor, and competitive bids submitted by the Company.
The majority of the Company's products are sold to customers located in North
America, primarily within the United States. The majority of the Company's
products are used in chemistry, physics, biology, and other general science
laboratories in the pharmaceutical, biotechnology, industrial, chemical,
commercial, education, government, and health care markets.

Cash and Cash Equivalents Cash and cash equivalents consist of cash on hand and
highly liquid investments with original maturities of three months or less.

Inventories Inventories are valued at the lower of cost or market. Cost has been
determined using the last-in, first-out (LIFO) method for all inventories.

Property, Plant and Equipment Property, plant and equipment are stated at cost
less accumulated depreciation. Depreciation is determined for financial
reporting purposes, principally on the straight-line method over the estimated
useful lives of the individual assets or, for leaseholds, over the terms of the
related leases, if shorter. Straight-line and accelerated methods of
depreciation have been used for income tax purposes. The lives, by category,
generally are as follows: buildings and improvements, 10-40 years; leasehold
improvements, 10 years; furniture, fixtures and office equipment, 3-5 years;
computer equipment, 3-5 years; factory machinery and vehicles, 5-10 years.
Management reviews the carrying value of property, plant and equipment for
impairment whenever changes in circumstances or events indicate that such
carrying value may not be recoverable.

Use of Estimates The presentation of financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the amounts reported in the financial statements and
accompanying notes. Actual results could differ from these estimates.
Significant estimates impacting the accompanying financial statements relate to
the allowance for uncollectible accounts receivable, inventory valuation, and
pension liabilities.

Fair Value of Financial Instruments The Company's financial instruments include
cash and cash equivalents, cash surrender value of life insurance policies, and
short-term borrowings. Management believes the carrying value of these assets
and liabilities approximate fair value.

Sales Recognition Product sales are generally recognized at the date of shipment
or upon completion of the product, where customers have made purchases but have
requested the Company to store the goods on the customer's behalf. Service
revenue for installation of product sold is recognized as the work is performed.
Accounts receivable includes retainage in the amounts of $1,971,000 and
$2,025,000 at April 30, 2000 and April 30, 1999, respectively, on certain sales
made under contractual agreements. Warranty costs are expensed as incurred.

Credit Concentration The Company's credit risk is generally not concentrated
with any one customer or industry, although the Company does enter into large
contracts with individual customers from time to time. The Company performs
credit evaluations of its customers.

Income Taxes Deferred income taxes reflect the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial
reporting purposes and the amounts used for income tax purposes.


                                                                         Page 13
<PAGE>

Advertising Costs The Company expenses advertising costs as incurred, including
trade shows, training materials, sales samples, catalogs, and other related
expenses. Advertising costs for the years ended April 30, 2000, 1999, and 1998
were $714,000, $913,000, and $812,000, respectively.

Earnings Per Share In fiscal year 1998, the Company adopted SFAS No. 128,
"Earnings Per Share." Basic earnings per share is based on the weighted average
number of common shares outstanding during the year. Diluted earnings per share
reflects the assumed exercise and conversion of outstanding options under the
Company's stock option plans, except when options have an antidilutive effect.

Reclassifications Certain prior year accounts have been reclassified to conform
with current year presentation.

Recent Accounting Standards In June 1998, the Financial Accounting Standards
Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No.
133, "Accounting for Derivative Instruments and Hedging Activities," which
establishes new standards of accounting and reporting for derivative instruments
and hedging activities. In June 1999, the FASB issued SFAS No. 137, which
deferred the effective date of adoption of SFAS No. 133 to June 15, 2000. The
Company will adopt SFAS No. 133 in the first fiscal quarter of 2001, and does
not expect the adoption to have a material effect on its financial condition or
results of operations.

Note 2--Inventories

The Company's inventories at April 30 consisted of:

  $ in thousands                                           2000             1999
  ------------------------------------------------------------------------------
  Finished goods                                         $  673           $  594
  Work-in-process                                           932              911
  Materials and components                                1,894            1,435
  ------------------------------------------------------------------------------
  Total inventories                                      $3,499           $2,940
  ------------------------------------------------------------------------------

If inventories had been determined using the first-in, first-out (FIFO) method
at April 30, 2000 and 1999, reported inventories would have been $2.2 million
greater in each of these years.

Note 3--Credit Arrangements

In January 1999, the Company entered into a credit facility with a bank to
borrow up to $3 million under a two-year unsecured revolving credit component
and up to $5 million under a seven-year equipment loan component. All advances
under the equipment loan component must be made during the first two years of
the agreement and must be secured by qualifying machinery and equipment.

The Company provides monthly interest payments under both components of the
facility calculated at the lower of (1) the LIBOR Market Index Rate plus 1.75%,
or (2) the lender's Prime Rate minus .75%. The borrowing rate was 8.04% at April
30, 2000. Beginning in the third year of the equipment loan, monthly principal
payments will be required in 60 equal installments. The equipment loan includes
financial covenants with respect to the Company's tangible net worth, funds flow
coverage, current ratio, and ratio of liabilities to tangible net worth.

At April 30, 2000, advances of $2,555,000 were outstanding under the revolving
credit loan. No advances were outstanding under the equipment loan.


Page 14
<PAGE>

Note 4--Income Taxes

The income tax expense consisted of the following:

$ in thousands                                   2000         1999        1998
- --------------------------------------------------------------------------------
Current tax expense:
    Federal                                    $ 1,320      $ 1,417     $ 1,047
    State and local                                185          318         311
- --------------------------------------------------------------------------------
Total current tax expense                        1,505        1,735       1,358
- --------------------------------------------------------------------------------
Deferred tax expense (benefit):
    Federal                                         42          395         327
    State and local                               (297)          84         (11)
- --------------------------------------------------------------------------------
Total deferred tax expense (benefit)              (255)         479         316
- --------------------------------------------------------------------------------
Net income tax expense                         $ 1,250      $ 2,214     $ 1,674
- --------------------------------------------------------------------------------

The reasons for the differences between the above net income tax expense and the
amounts computed by applying the statutory federal income tax rates to earnings
before income taxes are as follows:

$ in thousands                                    2000         1999        1998
- --------------------------------------------------------------------------------
Income tax expense at statutory rate            $ 1,636      $ 1,907     $ 1,441
State and local taxes, net of federal
 income tax benefit                                 221          266         198
Tax credits                                        (654)          --          --
Other                                                47           41          35
- --------------------------------------------------------------------------------
Net income tax expense                          $ 1,250      $ 2,214     $ 1,674
- --------------------------------------------------------------------------------

Significant items comprising the Company's deferred tax assets and liabilities
as of April 30 were as follows:

$ in thousands                                              2000          1999
- --------------------------------------------------------------------------------
Deferred tax assets:
  Accrued employee benefit expenses                       $   800       $   581
  Allowance for doubtful accounts                             208           168
  Inventory reserves and capitalized costs                    135           234
  Other                                                         8            43
- --------------------------------------------------------------------------------
 Total deferred tax assets                                  1,151         1,026
- --------------------------------------------------------------------------------
Deferred tax liabilities:
  Book basis in excess of tax basis
    of property, plant and equipment                         (944)       (1,074)
- --------------------------------------------------------------------------------
Total deferred tax liabilities                               (944)       (1,074)
- --------------------------------------------------------------------------------
 Net deferred tax assets (liabilities)                    $   207       $   (48)
- --------------------------------------------------------------------------------



                                                                         Page 15
<PAGE>

Note 5--Stock Options

During fiscal year 1992, stockholders approved the 1991 Key Employee Stock
Option Plan. During fiscal year 1997, stockholders approved an amendment to
increase the number of shares available for options under the plan from 130,000
to 230,000. Options are granted at not less than the fair market value at the
date of grant. Options are exercisable in such installments, for such terms (up
to 10 years), and at such times, as the Board of Directors may determine at the
time of the grant. At April 30, 2000, there were 43,850 shares available for
future grants under the plan.

During fiscal year 1994, the stockholders approved the 1993 Stock Option Plan
for Directors. This plan allows the Company to grant options on 40,000 shares of
the Company's common stock. Each non-employee director of the Company is
eligible to receive an option to purchase 5,000 shares of the Company's common
stock on the effective date of the plan or on the date of commencement of
service as a director. Options are exercisable in four equal, annual
installments and expire five years from the date of grant. Options are granted
at the fair market value at the date of grant. At April 30, 2000, there were
10,000 shares available for future grants under the plan.

The Company utilized treasury stock to satisfy the stock options exercised
during fiscal years 2000, 1999, and 1998. Stock option activity and weighted
average exercise price is summarized as follows:

<TABLE>
<CAPTION>
                                            2000                   1999                  1998
                                  --------------------------------------------------------------------
                                    Options       Price    Options       Price    Options      Price
- ------------------------------------------------------------------------------------------------------
<S>                                 <C>        <C>         <C>        <C>         <C>        <C>
Outstanding at beginning of year    124,500    $    6.85   110,250    $    4.48   151,375    $   3.69
Granted                              28,150        10.38    35,750        12.00    24,500        8.13
Canceled                             (7,000)       10.34        --           --   (16,750)       4.50
Exercised                           (29,875)        3.82   (21,500)        3.25   (48,875)       3.88
- ------------------------------------------------------------------------------------------------------
Outstanding at end of year          115,775    $    8.28   124,500    $    6.85   110,250    $   4.48
- ------------------------------------------------------------------------------------------------------
Exercisable at end of year           47,568    $    5.80    46,304    $    4.34    43,625    $   3.90
- ------------------------------------------------------------------------------------------------------
</TABLE>

The options outstanding and weighted average exercise price within the following
price ranges at April 30, 2000 are as follows:
<TABLE>
<CAPTION>
Exercise price range                              $2.31 - $3.25   $3.87 - $4.62   $8.13 - $12.00
- --------------------------------------------------------------------------------------------------
<S>                                                   <C>        <C>          <C>
Options outstanding                                     8,625         30,250          76,900
Weighted average exercise price                         $2.66          $4.10          $10.55
Weighted average remaining contractual life (years)       5.1            5.0             8.5
- --------------------------------------------------------------------------------------------------
</TABLE>

The options exercisable and weighted average exercise price within the following
price ranges at April 30, 2000 are as follows:

<TABLE>
<CAPTION>

Exercise price range              $2.31 - $3.25   $3.87 - $4.62   $8.13 - $12.00
- ------------------------------------------------------------------------------------
<S>                               <C>             <C>             <C>
Options exercisable                   8,625           23,750          15,193
Weighted average exercise price       $2.66            $4.16          $10.15
- ------------------------------------------------------------------------------------
</TABLE>

Fair Value Disclosures The Company applies APB Opinion No. 25 and its related
interpretations in accounting for its stock option plans. Accordingly, no
compensation cost has been recognized for these plans. Had compensation costs
for these plans been determined based on the fair value at the grant dates for
awards under the plans consistent with the method of SFAS No. 123, the Company's
net earnings and net earnings per share for fiscal years 2000, 1999, and 1998
would have been reduced to the pro forma amounts indicated below:


Page 16
<PAGE>

                                           2000        1999        1998
- ------------------------------------------------------------------------
Net earnings (in thousands)
As reported                              $3,561      $3,396      $2,563
Pro forma                                 3,488       3,332       2,539
- ------------------------------------------------------------------------
Net earnings per share - Basic
As reported                              $ 1.45      $ 1.40      $ 1.07
Pro forma                                  1.42        1.37        1.06
- ------------------------------------------------------------------------
Net earnings per share - Diluted
As reported                              $ 1.44      $ 1.38      $ 1.06
Pro forma                                  1.41        1.35        1.05
- ------------------------------------------------------------------------

The estimated weighted average fair value of options granted under the Company's
stock option plans was $4.74 in 2000, $5.91 in 1999, and $3.96 in 1998. The
options were valued using the Black-Scholes option-pricing model with the
following assumptions used for 2000, 1999, and 1998: dividend yield of 2.5%,
2.0%, and 2.0%; expected volatility of 49%, 52%, and 49%; risk-free interest of
5.81%, 5.20%, and 6.27%; and an expected life of 7.25 years.

Note 6--Commitments and Contingencies

The Company is involved in certain claims and legal proceedings in the normal
course of business which management believes will not have a material adverse
effect on the financial condition or results of operations of the Company.

The Company has entered into various operating lease agreements for machinery
and equipment. Most leases provide the Company with certain early cancellation
rights, as well as renewal and purchase options. Rent expense was $578,000,
$577,000, and $556,000 in fiscal years 2000, 1999, and 1998, respectively.

Under the terms of these agreements, future minimum lease payments for the years
ended April 30 are as follows:

$ in thousands                 Amount
- --------------------------------------
2001                          $   491
2002                              322
2003                              287
2004                              274
2005                              132
Thereafter                        152
- --------------------------------------
Total minimum lease payments   $1,658
- --------------------------------------

Note 7--Retirement Benefits

The Company has non-contributory defined benefit pension plans covering
substantially all salaried and hourly employees. The defined benefit plan for
salaried employees provides pension benefits that are based on each employee's
years of service and average annual compensation during the last 10 consecutive
calendar years of employment. The benefit plan for hourly employees provides
benefits at stated amounts based on years of service. The Company's funding
policy is to make quarterly contributions to fund the plans during the
participant's working lifetime, which have met ERISA's funding requirements.
Plan assets consist primarily of mutual funds.


                                                                         Page 17
<PAGE>

The Company has a defined contribution plan covering substantially all salaried
and hourly employees. The plan provides benefits to all employees who have
attained age 21, completed six months of service, and who elect to participate.
The Company makes matching contributions equal to 50% of the qualifying employee
contribution, up to a maximum employer contribution of 2% of the participant's
compensation. Contributions by the Company in fiscal years 2000, 1999, and 1998
were $239,000, $213,000, and $197,000, respectively.

The change in benefit obligations and the change in fair value of plan assets
for the non-contributory defined pension plans for each of the years ended April
30 are summarized as follows:

$ in thousands                                             2000          1999
- -------------------------------------------------------------------------------
Change in Benefit Obligations
Benefit obligations, beginning of year                    $7,774        $6,924
Service cost                                                 349           340
Interest cost                                                558           512
Actuarial (gain) loss                                       (791)          270
Actual benefits paid                                        (305)         (272)
- -------------------------------------------------------------------------------
Benefit obligations, end of year                          $7,585        $7,774
- -------------------------------------------------------------------------------
Change in Plan Assets
Fair value of plan assets, beginning of year              $7,007        $6,396
Actual return on plan assets                                 258            51
Actual company contributions                                 124           832
Actual benefits paid                                        (305)         (272)
- -------------------------------------------------------------------------------
Fair value of plan assets, end of year                    $7,084        $7,007
- -------------------------------------------------------------------------------
Funded Status and Prepaid (Accrued)
Funded status of plans                                    $ (501)       $ (767)
Unrecognized net transition obligation                        --           (32)
Unrecognized prior service cost                               84            95
Unrecognized net loss                                        467           916
- -------------------------------------------------------------------------------
Prepaid pension cost                                      $   50        $  212
- -------------------------------------------------------------------------------
Amounts Recognized in the
Statement of Financial Position
- -------------------------------------------------------------------------------
Prepaid pension cost                                      $   50        $  212
- -------------------------------------------------------------------------------
Weighted-Average Assumptions
Discount rate, end of year                                 8.00%         7.25%
Expected return on plan assets                             9.00%         9.00%
Rate of compensation increase                              5.00%         5.00%
- -------------------------------------------------------------------------------

The components of the net periodic pension costs for each of the three years
ended April 30 are as follows:

Net Periodic Pension Cost                          2000     1999          1998
- -------------------------------------------------------------------------------
Service cost                                       $349     $340          $254
Interest cost                                       558      512           451
Expected return on plan assets                     (623)    (582)         (464)
Amortization of transition asset                    (32)     (32)          (32)
Amortization of prior service cost                   11       11            11
Recognition of net loss                              24       19            15
- -------------------------------------------------------------------------------
Net periodic pension cost                          $287     $268          $235
- -------------------------------------------------------------------------------


Page 18
<PAGE>

Note 8--Segment Information

The Company's operations are classified into two business segments: laboratory
products and technical products. The laboratory products segment principally
designs, manufactures, and installs steel and wood laboratory furniture,
worksurfaces, and fume hoods. The technical products segment principally
manufactures and sells technical furniture including network storage systems,
workstations, workbenches, computer enclosures, and related accessories. Sales
to individual foreign countries did not exceed 2% of any segment sales.

Profits by business segment represent net revenues, less costs associated with
goods sold and operating expenses. Intersegment transactions are recorded at
normal profit margins with appropriate eliminations of intercompany profits.
Portions of corporate expenses are included in each segment. Unallocated
corporate expenses are included in the corporate column below. Corporate assets
include LIFO inventory reserve, fixed assets, deferred tax assets, prepaid
expenses, and cash surrender value of life insurance policies.

The following table shows net sales, profits, and other financial information by
business segment for the fiscal years ended April 30, 2000, 1999, and 1998:

<TABLE>
<CAPTION>
                                            Laboratory  Technical
 $ in thousands                              Products   Products  Corporate     Total
- ---------------------------------------------------------------------------------------
<S>                                            <C>       <C>         <C>      <C>
Fiscal Year Ended April 30, 2000:
Revenues from external customers               $61,678   $13,120    $   --    $74,798
Intersegment revenues                               --       319      (319)        --
Depreciation                                     1,699       263         6      1,968
Segment profit                                   3,541     1,451      (181)     4,811
Segment assets                                  30,867     6,320     2,129     39,316
Expenditures for segment fixed assets            3,210       139         3      3,352
Net sales to customers in foreign countries      2,399       277        --      2,676
- ---------------------------------------------------------------------------------------
Fiscal Year Ended April 30, 1999:
Revenues from external customers               $67,633   $ 9,845    $   --    $77,478
Intersegment revenues                               --       424      (424)        --
Depreciation                                     1,322       236         7      1,565
Segment profit                                   5,239       567      (196)     5,610
Segment assets                                  29,243     5,237     1,555     36,035
Expenditures for segment fixed assets            3,524       154        --      3,678
Net sales to customers in foreign countries      1,897     1,115        --      3,012
- ---------------------------------------------------------------------------------------
Fiscal Year Ended April 30, 1998:
Revenues from external customers               $62,598   $10,439    $   --    $73,037
Intersegment revenues                               --       782      (782)        --
Depreciation                                     1,100       205         7      1,312
Segment profit                                   3,696     1,315      (774)     4,237
Segment assets                                  24,587     5,339     1,940     31,866
Expenditures for segment fixed assets            1,261       259        --      1,520
Net sales to customers in foreign countries        984     2,525        --      3,509
- ---------------------------------------------------------------------------------------
</TABLE>

Revenues from one customer of the Company represented 11%, 12%, and 13% of the
Company's total sales in fiscal years 2000, 1999, and 1998, respectively.


                                                                         Page 19
<PAGE>

- --------------------------------------------------------------------------------
REPORT OF INDEPENDENT ACCOUNTANTS
- --------------------------------------------------------------------------------

To the Stockholders and Board of Directors of Kewaunee Scientific Corporation

In our opinion, the accompanying balance sheets and the related statements of
operations, of stockholders' equity and of cash flows present fairly, in all
material respects, the financial position of Kewaunee Scientific Corporation
(the "Company") at April 30, 2000 and 1999 and the results of its operations and
its cash flows for each of the three years in the period ended April 30, 2000,
in conformity with accounting principles generally accepted in the United
States. These financial statements are the responsibility of the Company's
management; our responsibility is to express an opinion on these financial
statements based on our audits. We conducted our audits of these statements in
accordance with auditing standards generally accepted in the United States which
require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, and evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for the opinion expressed above.

PRICEWATERHOUSECOOPERS LLP
Charlotte, North Carolina
May 31, 2000

- --------------------------------------------------------------------------------
MANAGEMENT'S REPORT ON FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------

To the Stockholders and Board of Directors of Kewaunee Scientific Corporation

The financial statements and accompanying notes were prepared by management,
which is responsible for their integrity and objectivity. Management believes
the financial statements, which include amounts based on judgments and
estimates, fairly reflect the Company's financial position and operating
results, in accordance with generally accepted accounting principles. All
financial information in this annual report is consistent with the financial
statements.

Management maintains internal accounting control systems and related policies
and procedures designed to provide reasonable assurance that assets are
safeguarded, that transactions are properly recorded and executed in accordance
with management's authorization, and that accounting records may be relied upon
for the preparation of financial statements and other financial information. The
design, monitoring, and revision of internal accounting control systems involve,
among other things, management's judgment with respect to the relative cost and
expected benefits of specific control measures.

The Company's financial statements have been audited by independent accountants
who have expressed their opinion with respect to the fairness of those
statements. Their audits included consideration of the Company's internal
accounting control systems and related policies and procedures. They advise
management and the Audit Committee of significant matters resulting from their
audits.

D. Michael Parker
Vice President, Finance
Chief Financial Officer


Page 20
<PAGE>

- --------------------------------------------------------------------------------
SUMMARY OF SELECTED FINANCIAL DATA
- --------------------------------------------------------------------------------

                                                 Kewaunee Scientific Corporation

<TABLE>
<CAPTION>
$ and shares in thousands,
except per share data                    2000         1999       1998        1997       1996
- ------------------------------------------------------------------------------------------------
<S>                                     <C>         <C>         <C>         <C>         <C>
Operating Statement Data:
- ------------------------------------------------------------------------------------------------
Net sales                               $74,798     $77,478     $73,037     $61,961     $57,559
Costs of products sold                   57,715      59,782      55,600      47,996      46,835
- ------------------------------------------------------------------------------------------------
Gross profit                             17,083      17,696      17,437      13,965      10,724
Operating expenses                       12,429      12,315      13,096      11,496       9,827
- ------------------------------------------------------------------------------------------------
Operating earnings                        4,654       5,381       4,341       2,469         897
Other income, net                           326         325          45          41         158
Interest expense                           (169)        (96)       (149)       (344)       (694)
- ------------------------------------------------------------------------------------------------
Earnings before income taxes              4,811       5,610       4,237       2,166         361
Income tax expense (benefit)              1,250       2,214       1,674         (97)         --
Net earnings                            $ 3,561     $ 3,396     $ 2,563     $ 2,263     $   361
- ------------------------------------------------------------------------------------------------
Weighted average shares outstanding:
  Basic                                   2,456       2,432       2,386       2,366       2,367
  Diluted                                 2,478       2,464       2,423       2,391       2,372
- ------------------------------------------------------------------------------------------------
Per Share Data:
- ------------------------------------------------------------------------------------------------
Net earnings:
  Basic                                 $  1.45     $  1.40     $  1.07     $  0.96     $  0.15
  Diluted                                  1.44        1.38        1.06        0.95        0.15
Cash dividends                             0.26         .22        0.18        0.08          --
Year-end book value                       10.19        9.04        7.89        7.01        6.13
- ------------------------------------------------------------------------------------------------
Balance Sheet Data:
- ------------------------------------------------------------------------------------------------
Current assets                          $23,032     $21,831     $20,853     $16,465     $15,646
Current liabilities                      11,560      11,672      11,287       9,460      10,599
Net working capital                      11,472      10,159       9,566       7,005       5,047
Net property, plant and equipment        13,506      12,125      10,034       9,826      10,308
Total assets                             39,316      36,035      31,866      26,991      26,504
Total borrowings/long-term debt           2,555         939        --          --         2,648
Stockholders' equity                     25,135      22,032      19,039      16,586      14,515
- ------------------------------------------------------------------------------------------------
Other Data:
- ------------------------------------------------------------------------------------------------
Capital expenditures                    $ 3,352     $ 3,678     $ 1,520     $ 1,163     $   812
Year-end stockholders of record             334         349         365         392         409
Year-end employees                          606         643         619         560         499
- ------------------------------------------------------------------------------------------------
</TABLE>


                                                                         Page 21
<PAGE>

- --------------------------------------------------------------------------------
QUARTERLY FINANCIAL DATA (UNAUDITED)
- --------------------------------------------------------------------------------

Selected quarterly financial data for fiscal years 2000 and 1999 were as
follows:

$ in thousands,                  First       Second        Third        Fourth
except per share data           Quarter      Quarter      Quarter       Quarter
- --------------------------------------------------------------------------------
2000
Net sales                        $20,065      $19,551      $16,945      $18,237
Gross profit                       4,630        4,345        4,177        3,931
Net earnings                         904          740          879        1,038
Net earnings per share
 Basic                              0.37         0.30         0.36         0.42
 Diluted                            0.37         0.30         0.35         0.42
Cash dividends per share            0.06         0.06         0.07         0.07
- --------------------------------------------------------------------------------
1999
Net sales                        $19,624      $19,253      $18,404      $20,197
Gross profit                       4,422        4,024        4,102        5,148
Net earnings                         766          605          635        1,390
Net earnings per share
  Basic                             0.32         0.25         0.26         0.57
  Diluted                           0.31         0.25         0.26         0.56
Cash dividends per share            0.05         0.05         0.06         0.06
- --------------------------------------------------------------------------------

- --------------------------------------------------------------------------------
RANGE OF MARKET PRICES
- --------------------------------------------------------------------------------

Kewaunee's common stock is traded in the NASDAQ/Over-the-Counter Market, under
the symbol KEQU. The following table sets forth the quarterly high and low
prices reported on the NASDAQ National Market System.

         First   Second   Third  Fourth
        Quarter  Quarter Quarter Quarter
- -----------------------------------------
2000
High     10 5/8   11 1/2  10 1/8  13 3/4
Low      10 1/4   11 3/8  10 1/8  13 3/8
Close    10 5/8   11 3/8  10 1/8  13 7/16
- -----------------------------------------
1999
High     14 1/2   13      13 1/4  11 1/8
Low       9 3/4    9 1/2  10       9
Close    11 7/16  12 3/4  11 3/8  10 1/8
- -----------------------------------------

Page 22
<PAGE>

- --------------------------------------------------------------------------------
CORPORATE INFORMATION
- --------------------------------------------------------------------------------

Board of Directors
Margaret Barr Bruemmer (1)(2)(3)
  Attorney
  Milwaukee, WI

Wiley N. Caldwell (3)(4)
  Retired President
  W. W. Grainger, Inc.
  Kenilworth, IL

John C. Campbell, Jr. (1)(2)
  Private Consultant
  Arlington, TX

Kingman Douglass (2)(3)(4)
  Corporate Counselor
  Santa Barbara, CA

Eli Manchester, Jr. (1)(3)
  Chairman/CEO
  Kewaunee Scientific Corporation
  Statesville, NC

Thomas F. Pyle (3)(4)
  Chairman
  The Pyle Group, LLC
  Madison, WI

James T. Rhind (1)(4)
  Counsel to Bell, Boyd & Lloyd
  Attorneys
  Chicago, IL

William A. Shumaker (1)(3)
  President/COO
  Kewaunee Scientific Corporation
  Statesville, NC

(1) Executive Committee
(2) Audit Committee
(3) Financial/Planning Committee
(4) Compensation Committee

Executive Officers

Eli Manchester, Jr.
  Chairman,
  Chief Executive Officer

William A. Shumaker
  President,
  Chief Operating Officer

D. Michael Parker
  Vice President, Finance,
  Chief Financial Officer,
  Treasurer, Secretary

James J. Rossi
  Vice President, Human Resources

Kurt P. Rindoks
  Vice President, Engineering and
  General Manager Resin Materials Division
  Laboratory Products Group

Corporate Offices

2700 West Front Street
Statesville, NC 28677-2927
P.O. Box 1842, Statesville, NC 28687-1842
Telephone: 704-873-7202
Facsimile: 704-873-1275

Employment Opportunities

Individuals interested in employment with Kewaunee Scientific Corporation should
contact the Vice President of Human Resources, Kewaunee Scientific Corporation,
P.O. Box 1842, Statesville, NC 28687-1842. Employment opportunities are also
listed on the Internet at http://www.kewaunee.com. Kewaunee Scientific
Corporation is an equal opportunity employer.

[LOGO OF KEQU]

                                                                         Page 23
<PAGE>

- --------------------------------------------------------------------------------
STOCKHOLDER INFORMATION
- --------------------------------------------------------------------------------

Financial Information

The Company's Form 10-K financial report, filed annually with the Securities and
Exchange Commission, may be obtained by stockholders without charge by writing
the Secretary of the Company, Kewaunee Scientific Corporation, P.O. Box 1842,
Statesville, NC 28687-1842.

Recent financial information is available on the Internet at
http://www.kewaunee.com.

Independent Accountants

PricewaterhouseCoopers LLP
Charlotte, NC

Notice of Annual Meeting

The Annual Meeting of Stockholders of Kewaunee Scientific Corporation will be
held in the 37th floor Annual Meeting Room at Harris Trust & Savings Bank,
Chicago, IL on August 23, 2000 at 10:00 a.m. Central Daylight Time.

Transfer Agent and Registrar

All stockholder inquiries, including transfer-related matters, should be
directed to:
ChaseMellon Shareholder Services, LLC
Overpeck Centre
85 Challenger Road
Ridgefield Park, NJ 07660
Telephone: 800-288-9541
Internet at http://www.chasemellon.com

- --------------------------------------------------------------------------------
PRODUCT INFORMATION
- --------------------------------------------------------------------------------

Kewaunee Scientific Corporation products are available through a network of
sales representatives and a national stocking distributor.

For more information on the Company's laboratory products, contact the Marketing
Services Department in Statesville, NC; telephone: 704-873-7202; on the Internet
at http://www.kewaunee.com; e-mail: marketing@kewaunee.com.

For more information on the Company's technical products, contact the Customer
Service Department in Lockhart, TX; telephone: 512-398-5292; on the Internet at
http://www.kewaunee.com; e-mail: custsvc@kewaunee-tpg.com.

- --------------------------------------------------------------------------------
TRADEMARKS
- --------------------------------------------------------------------------------

Advantage, Alpha, BasikBench, CFHS, Discovery, Evolution, Explorer, FlexTech,
Kemresin, Kemrock, Kemshield, Kewaunee, Signature, Silhouette, Sturdilite,
Supreme Air, TechStat, The Research Collection, Trademark, and Visionaire are
registered trademarks of Kewaunee Scientific Corporation. ADJUSTAbench is a
pending trademark of Kewaunee Scientific Corporation.


Page 24
<PAGE>

                               [LOGO OF KEWAUNEE]

Copyright 2000                                           Printed in U.S.A. 7/00
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-27
<SEQUENCE>6
<FILENAME>0006.txt
<DESCRIPTION>FINANCIAL DATA SCHEDULE
<TEXT>

<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          APR-30-2000
<PERIOD-START>                             MAY-01-1999
<PERIOD-END>                               APR-30-2000
<CASH>                                               9
<SECURITIES>                                         0
<RECEIVABLES>                                   17,993
<ALLOWANCES>                                       490
<INVENTORY>                                      3,499
<CURRENT-ASSETS>                                23,032
<PP&E>                                          33,242
<DEPRECIATION>                                  19,736
<TOTAL-ASSETS>                                  39,316
<CURRENT-LIABILITIES>                           11,560
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         6,550
<OTHER-SE>                                      18,585
<TOTAL-LIABILITY-AND-EQUITY>                    39,316
<SALES>                                         74,798
<TOTAL-REVENUES>                                74,798
<CGS>                                           57,715
<TOTAL-COSTS>                                   57,715
<OTHER-EXPENSES>                                12,429
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 169
<INCOME-PRETAX>                                  4,811
<INCOME-TAX>                                     1,250
<INCOME-CONTINUING>                              3,561
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,561
<EPS-BASIC>                                       1.45
<EPS-DILUTED>                                     1.44


</TABLE>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
